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ABSTRACT 
ASSESSING BASELINE AND POST-DISCHARGE RISK FACTORS IN SUBJECTS WITH 
AND WITHOUT SLEEP APNEA UNDERGOING ENDOSCOPY WITH DEEP SEDATION 
 
 
Background: Outpatient procedures encompass over 60% of all surgeries in the United States, 
and the prevalence of obstructive sleep apnea (OSA) remains high among adult surgical 
ambulatory patients. Ambulatory surgery poses problems for patients with OSA because 
narcotics and anesthetics used during surgery can complicate the negative effects of OSA, 
leading to cardiac events, brain hypoxia, and even death. This study was designed to evaluate the 
prevalence of cardiopulmonary risk factors among post endoscopic patients with diagnosed and 
undiagnosed sleep apnea. Methods: The study involved a prospective, descriptive cross-sectional 
design and incorporated a pre-test or post-test data collection approach, using Actigraphy, pulse 
oximetry and 24-hour ECG monitoring via Bluetooth technology to monitor outpatients 
undergoing endoscopy with deep Propofol sedation. Patients were recruited pre-procedure to 
obtain a resting baseline ECG, and pre-procedure values were then monitored post procedure 
continuously for 24 hours. A p-value less than 0.05 was considered to be statistically significant. 
A target sample included 50 adult outpatients from a Florida suburban endoscopy center. 
Results: Pulse oximetry and Actigraph scores revealed no difference based on OSA. The 
ANOVA for oxygen desaturation events and sleep quality indices reflected no differences across 
groups. Sleep quality had no measurable influence on adverse events and was similar across 
groups; participants diagnosed with OSA slept longer than those in the untreated or no OSA 
group. Regressions for sleep quality indices reflected no differences among groups. Conclusions: 
There remains a lack of literature on cardiopulmonary and ECG indicators of cardiac risks in 
patients with OSA in the 24 hours following discharge from ambulatory surgery. This 
xii 
 
 
 
dissertation characterized the ECG at baseline and post-discharge among post-endoscopy 
outpatients with OSA and without OSA. Further research is recommended. 
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Chapter 1: The Problem 
 
 
Introduction 
Background of the Problem 
Sleep disordered breathing refers to the entire spectrum of sleep-related breathing 
abnormalities including upper airway resistance syndrome with and without snoring, central 
sleep apnea, and obstructive sleep apnea (OSA; Garcha, Aboussouan, & Minai, 2013). OSA is a 
sleep disorder that involves intermittent or complete obstruction of the airway during sleep 
(Garcha et al., 2013). OSA is associated with several negative consequences including 
cardiovascular disorders, neurocognitive dysfunctions, and metabolic dysfunction, and exists in 
an estimated 3 to 7.5% of the population of the United States (Mador, 2013). The prevalence of 
OSA is increasing in the general population and remains high among adult surgical patients, 
including patients of ambulatory surgery (Joshi, Ankichetty, Gan, & Chun, 2012; Mador, 2013; 
Singh, Liao, & Kobah, 2013). Benumof (2016) urged anesthetists to effect immediate change by 
addressing OSA in surgical patients because of the high risk of adverse outcomes and death. The 
current study represents an answer to that call and was designed to examine the clinical and ECG 
risk factors of cardiac risks in OSA patients in the 24 hours immediately following discharge 
from ambulatory surgery. 
Ambulatory surgery refers to any surgical procedure that allows the patient to go home 
the same day (Hall, Schwartzman, Zhang, & Liu, 2017). The number of ambulatory surgeries 
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performed nationwide in hospital outpatient departments or freestanding ambulatory centers has 
grown exponentially from 3.7 million to over 48 million in the period spanning 1981 to 2010 
(Hall et al., 2017). Outpatient procedures encompassed over 60% of all surgeries in the United 
States in 2011, as compared to 19% in 1981(American Hospital Association, 2014). 
Ambulatory surgery can pose serious problems for patients with OSA because sedatives 
and anesthesia used during surgery may complicate and compound the negative effects of OSA, 
leading to cardiac events, brain hypoxia, and even death (Joshi et al., 2012; Mador, 2013). The 
possibility of these adverse events poses unique risks to ambulatory surgery patients because 
post-operative patients are released into settings lacking skilled nursing care (Kent, Metzner, & 
Bollag, 2014). Although studies focused on post-operative recovery of outpatients with OSA in 
hospital settings are beginning to emerge, few researchers have monitored and studied the post-
operative recovery of outpatients with OSA in patients’ homes (cf. Biddle et al., 2016). There is 
still scarce information on the negative consequences for ambulatory surgery patients at home in 
the immediate post-operative period and particularly for those patients with undiagnosed 
moderate to severe OSA. 
Statement of the Problem 
There are an increasing number of ambulatory surgeries, such as endoscopic procedures, 
as well as an increasing number of patients with OSA undergoing surgery in ambulatory settings 
(Hall et al., 2017; Joshi et al., 2012). Information on the negative consequences for ambulatory 
surgery patients and particularly those with OSA shortly after being discharged from ambulatory 
surgery was scarce. It is important that patients who have diabetes, hypertension, coronary artery 
disease, or pulmonary disease be adequately assessed and prepared based on the needs of their 
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conditions before surgery. The current study helped identify whether selected patients with OSA 
risk factors require special care prior to and after their procedures. 
Purpose of the Study 
The purpose of this study was to assess the prevalence of patient risk factors for 
cardiopulmonary adverse events in a diverse range of patients presenting for outpatient 
endoscopy under deep propofol sedation, and to determine the relative risk of adverse 
cardiopulmonary events occurring in the first 24-hours post-procedure following deep propofol 
sedation for endoscopy in patients with or without OSA. The proposed study was designed to 
evaluate the prevalence of cardiopulmonary risk factors among post endoscopic patients with 
diagnosed and undiagnosed sleep apnea. In doing so, the study made a meaningful contribution 
to the literature regarding the outcomes and management of patients with undiagnosed and 
untreated OSA in the Ambulatory Surgery Center (ASC) environment. It further helped to define 
the associated risks and inform decisions outlining care for ASC patients. For instance, 
diagnosing sleep apnea and prescribing continuous positive airway pressure (CPAP) therapy, 
prior to surgery, significantly reduced postoperative cardiovascular complications, specifically 
cardiac arrest and shock, by more than half (Mutter, Chateau, & Moffatt, 2014). This study 
provided additional data for future projects on ensuring preoperative preparedness and 
postoperative monitoring, while triggering identification and risk amelioration in this burgeoning 
population of patients. 
Rationale and Theoretical Framework 
According to the Centers for Disease Control and Prevention, the rate of sleep disorders 
has reached epidemic proportions, affecting 1 in 3 American adults (Liu et al., 2014). Sleep 
disorders and OSA are associated with adverse events ranging from loss of productivity to 
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increased risk of cardiopulmonary illness and related death (Gami et al., 2013). The National 
Center on Sleep Disorders Research, a subsidiary of the National Heart, Lung, and Blood 
Institute within the National Institutes of Health, was established in 1993 to address this serious 
public health concern. The most current NIH Sleep Disorders Research Plan was released in 
2011, with the overall goal of better understanding sleep disorders and circadian biology to 
develop therapies that will make a significant impact on this serious public health epidemic 
(National Center on Sleep Disorders Research, 2011). With OSA in epidemic proportions, 
greater research is needed on OSA among ambulatory surgery patients released from clinical 
settings within 24-hours post-procedure. 
Almost two decades since the U.S. Institute of Medicine report, To Err Is Human (1999), 
most errors in patient care are still caused by faulty systems, processes, and conditions that lead 
people to make mistakes or fail to prevent them. As many as 25% of patients undergoing surgery 
have OSA, but few hospitals or ASCs have policies that address the risks of this condition during 
the perioperative period, and fewer follow recommended consensus statements (Joshi et al., 
2012). How patients with OSA are identified, determined suitable for ambulatory surgery, and 
discharged after ambulatory surgery represents a trajectory of problems inherent within the 
system that can lead to potential patient harm (Joshi et al., 2012). Not considering the needs of 
patients with OSA in ASC settings and the possible associated cardiac sequelae represents a 
latent risk factor that can be mitigated by information generated by this study.  
Reason (2000) studied error management in clinical settings and developed the Swiss 
Cheese Model (SCM) that holds that most errors or accidents are caused not so much by 
inevitable human mistakes, but rather by an organization’s incomplete layers of error protection 
that allow errors to pass through unchecked on their way to causing harm. These layers of 
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protection are like slices of Swiss cheese with gaps that may allow errors to pass through 
unchecked on their way to causing harm. Holes in the SCM represent gaps in organizational 
defenses. However, unlike holes in real Swiss cheese, these holes are dynamic. They open, close, 
and change location over time. Holes in these layers of protection happen for two reasons: active 
failures and latent conditions (Reason, 2000).  
Active failures involve problematic acts committed by those in direct contact with 
patients or the system, and they take several forms (e.g., lapses, slips, mistakes, and procedural 
violations; Reason, 2000). Latent conditions refer to inevitable problems inherent within the 
system that arise from the decisions of procedure architects, upper level management, and 
designers (Reason, 2000). Holes in any one layer of protection may lead to errors that usually do 
not result in negative outcomes. Latent conditions may allow holes to align to permit a trajectory 
of accident opportunity, potentially bringing hazard or harm to the patient or system. The 
trajectory path will show that errors result from holes in multiple layers of safeguards (Reason, 
2000).  
This study is innovative because, to date, no researchers have reported both the clinical 
(e.g., actigraphy, pulse oximetry, anthropometric parameters, etc.) and electrocardiographic 
(ECG) indicators of cardiac risks that occur in this group of patients, particularly in the 24 hours 
immediately following discharge from ambulatory surgery (Rotenberg, 2013). Amidst this dearth 
of scientific evidence, organizations concerned with patient safety, such as the American Society 
of Anesthesiologists, have recommended that patients with OSA be observed for extended 
periods of time and routinely receive CPAP (Joshi et al., 2012). Lack of clinical and ECG 
indicators of cardiac risks in patients with OSA in the 24 hours immediately following discharge 
from ambulatory surgery may represent a gap in healthcare that may lead to adverse patient 
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outcomes. An innovative approach is necessary to report the clinical and ECG risk factors of 
cardiac risks that occur in OSA patients in the 24 hours immediately following discharge from 
ambulatory surgery. 
Some institutions require that certain populations of patients with OSA who have 
received particular narcotics be held overnight and not undergo surgery in ASCs (Rotenberg, 
2013). Healthcare providers are rightfully concerned about the increased risk of adverse events 
for OSA patients. Holding patients overnight may prove to be unnecessary and is inconsistently 
practiced (Memtsoudis & Stundner, 2014). The current study was designed to examine the 
clinical and ECG risk factors of cardiac risks in OSA patients in the 24 hours immediately 
following discharge from ambulatory surgery. 
Design and Methods 
Within this study, the researcher assessed the relationship between cardiac risk factors 
and OSA 24 hours before and after sedation. Data was collected before and after the treatment 
was administered. The study utilized a pre/post-procedure, prospective, descriptive cross-
sectional design. The primary goal of this study was to assess the baseline and post-discharge 
clinical and ECG risk factors of cardiac risk among post-endoscopy outpatients during the 24 
hours before and following discharge from the ASC. The participants received deep Propofol 
sedation during their procedure. This study aimed to determine whether participants with 
undiagnosed or untreated OSA have a higher risk of potentially fatal cardiac or respiratory events 
compared to patients using appropriate treatment for OSA (i.e., dental appliance, CPAP, and 
patients who do not have OSA. 
  
7 
 
Research Questions 
 The following research questions guide the study: RQ1: What is the prevalence of known 
ECG characteristics for cardiac events among pre-endoscopic patients with high and normal 
STOP-bang scores on resting 12-lead ECGs clinical (pulse oximetry and actigraph derived sleep 
quality scores) and ECG characteristics of cardiopulmonary risk in post-endoscopy outpatients 
with undiagnosed or untreated OSA, post-endoscopy outpatients receiving treatment for OSA, 
and post-endoscopy patients without OSA? 
 The variables included in the study for Research Question 1 were clinical (pulse oximetry 
and actigraph derived sleep quality scores) and ECG risk factors of cardiac risk. The researcher 
conducted descriptive statistics to address Research Question 1. Descriptive statistics were used 
to represent the prevalence of clinical (pulse oximetry and actigraph derived sleep quality 
scores), ECG risk factors and participant group: post-endoscopy outpatients with undiagnosed or 
untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and post-endoscopy 
patients without OSA. 
RQ2: Among post-endoscopic patients receiving propofol, using a rhythm event recorder 
(BodyGuardian Heart) are there statistically significant differences in the frequency of oxygen 
desaturation events and tachy-brady-arrhythmias over 24 hours between outpatients with 
undiagnosed or untreated OSA, and post-endoscopy patients with and without a medical 
diagnosis of OSA? 
 The researcher conducted analyses of variance (ANOVA) tests for Research Question 2. 
For Research Question 2, the dependent variables are ECG and pulse oximetry. These dependent 
variables were compared among three groups of participants: post-endoscopy outpatients with 
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undiagnosed or untreated OSA, post-endoscopy outpatients with a medical diagnosis of OSA 
who are using CPAP, and post-endoscopy patients without OSA. 
RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG, 
are there statistically significant differences in the duration of resting heart rate, QRS duration, 
QTC duration and ST segment deviation between outpatients with undiagnosed or untreated 
OSA, and post-endoscopy patients with and without a medical diagnosis of OSA? 
For Research Questions 3, the researcher conducted binary logistic regression to assess 
the amount of explained variance between sleep efficiency and cardiac adverse outcomes. 
Cardiac adverse outcomes were defined as the presence of bradycardia and tachycardia. The 
variables of interest for Research Question 3 are sleep quality and number of adverse events.  
RQ4: Does sleep quality influence pulse oximetry readings? The variables of interest for 
Research Question 4 are sleep quality and pulse oximetry readings this relationship was assessed 
using regression analyses.  
Clinical factors were operationalized as observations related to anthropomorphic 
measurements, oximetry results, and sleep during the data collection process. Cardiopulmonary 
risk factors comprised the 11 outcomes related to healthy cardiac function. An adverse event was 
defined as any negative medical occurrence following the use of Propofol sedation, regardless of 
its explicit connection to Propofol. Examples of adverse events would be decreased respiratory 
effort that resulted in sustained oxygen desaturations below 90% on room air or aggravation of 
or new onset arrhythmias. If the adverse event was deemed acutely detrimental, the participant 
was instructed to follow-up with their primary care physician. If the adverse event was not 
considered detrimental, no follow up steps were recommended. Sleep quality was 
operationalized as the sleep efficiency score from actigraphy.  
  
9 
 
The findings from the first research question addressed the dearth of literature related to 
the prevalence of clinical and ECG risk factors of cardiac risk in this burgeoning population of 
patients. Findings from the second research question provided information related to whether 
outpatients with undiagnosed OSA who receive sedation are subject to increased cardiac risk as 
determined by the presence of tachy-brady arrhythmias obtained from cardiac monitoring. The 
remaining questions regarding sleep quality were addressed by data retrieved from the actigraph 
watch and analyzed with the accompanying Action4 software package. Table 1 lists 
cardiopulmonary risk factors comprised the 11 outcomes related to healthy cardiac function.  
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Table 1:  Cardiopulmonary Risk Factors 
Variable Definition Variable Type Cutoff for 
Cardiac Events 
Clinical Significance 
HR Mean R-R interval of all QRS 
complexes during the duration of 
the recording 
Continuous > 75 beats per 
minute  
(Jouven et al.) 
Poor sympathetic tone 
QRS 
duration 
Mean QRS onset to offset duration 
of all leads on the standard 10-s 
ECG 
Continuous >120 ms 
(Goldberger et 
al.) 
Abnormal 
conduction/myocardial 
damage 
QTc  
Interval 
Mean QRS onset to T offset 
interval of all leads on the 
standard 10-s ECG corrected for 
HR using Bazett formula 
Continuous > 470 ms 
(women) or 
>450 ms (men) 
(Straus et al.) 
Abnormal global 
repolarization 
LVH The presence of this pattern on the 
standard 10-s ECG using Cornell 
voltage criteria 
Continuous >20 mm 
(women) or > 23 
mm (Priori et 
al.) 
Myocardial strain 
LBBB The presence of this pattern on the 
standard 10-s ECG using AHA 
criteria 
Dichotomous Present 
(Surawicz et al.) 
Abnormal 
conduction/myocardial 
damage 
fQRS RSR morphology > 2 R’ or 
notching in the nadir of S wave 
with a narrow QRS (<120ms) or > 
2 R’ or notching in the nadir of S 
wave with a widened QRS 
Dichotomous Present  
(Das et al.) 
Myocardial scarring 
ST event The presence of at least 1 episode 
of ST depression of >0.5 mm in 
leads V2-V3 or > 1 mm in all 
other leads in > or = 2 contiguous 
leads for at least 5 min at any time 
Dichotomous Present 
(Holmvang et 
al.) 
Transient myocardial 
ischemia 
PVC The presence of frequent 
premature ventricular contractions 
at rate of > or = 10 per hour for 
the duration of Holter recording. 
Dichotomous Present 
(Goldberger et 
al.) 
Vulnerability to fatal 
arrhythmia 
NSVT At least 1 episode of > or = 3 
consecutive ventricular beats at a 
rate of > 120 beats per minute 
Dichotomous Present 
(Goldberger et 
al.) 
Vulnerability to fatal 
arrhythmia 
Hypoxia Pulse oximeter reading < or 
= 90 percent 
Dichotomous Present  
(Cintra et al.) 
Vulnerability to fatal 
arrhythmia 
OSA 
Sleep 
Efficiency 
The intermittent cessation of 
breathing 
Ratio of total time spent 
asleep in a night compared 
to total time spent in bed. 
Continuous 
 
Continuous 
STOP-BANG 
> 3 
 
> 85% 
Vulnerability to 
arrhythmia 
Vulnerability to 
arrhythmia 
Note. Abbreviations: fQRS, fragmented QRS complex; HRV, HR variability; LBBB, Left bundle branch block; 
LVH, left ventricular hypertrophy; PVC, premature ventricular contraction; QTc, corrected QT interval, OSA; 
obstructive sleep apnea. 
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Importance of the Study 
Despite the numerous advancements in our understanding of the pathogenesis and 
clinical consequences of this disorder, a majority of those affected remain undiagnosed (Peppard, 
Young, & Barnet, 2013). The continued prevalence of OSA combined with obesity trends and 
hypertension puts the population at serious risk of mortality and morbidity. The lack of 
information on the clinical and ECG risk factors of cardiac risks that occur in OSA patients 
within the 24 hours immediately following discharge from ambulatory surgery may represent a 
structural shortcoming in healthcare leading to adverse patient outcomes (Reason, 2000). 
As is reflective of the dearth in epidemiological sleep studies, recent evaluations of the 
risks associated with undiagnosed moderate to severe OSA in surgical populations needs to be 
determined, but previous estimates show that OSA is more prevalent among surgical patients 
than in the general population (Singh et al., 2013). Further, there is a higher rate of perioperative 
complications in those with OSA compared to those without OSA (Peppard et al., 2013). ASCs 
offer patients the convenience of having surgical procedures performed outside of main hospital 
settings. The increased demand for these services, and the fact that over 10 million 
gastrointestinal (GI) endoscopic procedures are performed each year in the United States, 
suggests that hospitals and health care facilities must proactively manage the safety and 
economic implications of OSA patients (Joseph et al., 2016).  
Adverse in-hospital events for all ASC patients are less than 1%, with major morbidity 
occurring with a frequency of approximately 0.1% (Kent et al., 2014). There is a void in the 
literature regarding the consequences for OSA patients in the first 24 hours at home after 
discharge from the ASC. The long-term adverse effects of OSA on health outcomes are well 
documented, while effects in the perioperative arena have only recently been systematically 
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assessed (Kaw, Pasupuleti, Walker, Ramaswamy, & Foldvary-Schafer, 2012; Mutter, Chateau, & 
Moffatt, 2014; Peppard et al., 2013). To date there are no published studies that have included 
systematic, in-home cardiopulmonary monitoring (e.g., Actigraphy, electrocardiogram, pulse 
oximetry) of patients after discharge from ASCs. 
The present study involves an innovative approach, and patients were monitored for 24 
hours in their homes before their procedure and following ASC discharge. The Cardiac monitor 
was worn optimally overnight post procedure for up to 24 hours, as it is clinically important to 
evaluate at least 24 hours of cardiac monitor data because there is greater risk for adverse events 
in the first 24 hours (Zimetbaum & Goldman, 2010). The prevalence of OSA among candidates 
for elective endoscopies and colonoscopies is estimated to be greater than 40% largely due to the 
high rate of coexisting diseases such as obesity, hypertension, pulmonary disorders, and diabetes, 
as well as a high number of patients over the age of 50 years (Boese, Ransom, Roadfuss, Todd, 
& McGuire, 2014).  
Assumptions 
 The main assumption of this study was that ambulatory surgery patients, particularly 
those with undiagnosed sleep apnea, are especially vulnerable to cardiopulmonary peril once 
released from the immediate postoperative period in the post-anesthesia care unit (PACU) to 
their homes. 
Limitations 
This convenience sample itself was a limitation because it was not as representative as a 
random sample. Even though this study was limited to a convenience sample of endoscopy 
patients, it may still be representative of ambulatory surgery outpatients since endoscopy patients 
represent the largest proportion of ambulatory surgeries. Because of requirements and procedures 
  
13 
 
specific to other types of ambulatory procedures, results may not generalize well to patients 
undergoing ambulatory surgeries other than endoscopies. Additionally, another limitation to 
generalizability is that propofol is not standard for all ambulatory procedures, and the effects of 
other anesthesia on OSA patient’s post-procedure may differ from those of propofol. 
Scope and Delimitations 
This study was designed to measure the relationship between cardiac risk and OSA 24 
hours pre- and 24 hours post-sedation, with data being collected before and after the treatment is 
administered, using a pre/post-test, cross-sectional design. This study focused on the description 
of cardiopulmonary risks that may be encountered in ambulatory endoscopy patients, as 
monitored by pulse oximetry, cardiac monitor and actigraph. While some findings may be useful 
in the care of other categories of ambulatory patients, this study was not designed to examine the 
cardiopulmonary risks that may be observed in other outpatient populations such as other 
popular categories of ambulatory surgery, including orthopedic surgery and eye surgery. 
Summary 
 OSA is a public health crisis and an acknowledged epidemic. The burgeoning obesity 
epidemic with the accompanying demand for cost-effective, efficient, and safe ambulatory 
surgeries demand that health care professionals and anesthetists take responsibility for the safety 
of patients beyond the procedure room and PACU. 
 Chapter 2 includes a review of the current literature related to obstructive sleep apnea in 
general and in the ambulatory patient population in particular. Chapter 3 includes the 
methodological procedures used to answer the research hypotheses. Chapter 4 consist of data 
analysis derived from the pulse oximeter, cardiac monitor, and actigraph watch. Chapter 5 
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provides a summary of findings, conclusions based on the findings, and end with 
recommendations for implementation of safety initiatives and suggestions for further research. 
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Chapter 2: Review of the Literature 
 
 
Not much is known about what happens to ambulatory surgery patients on discharge. 
There may be significant changes in the cardiopulmonary status of ASC patients that are 
unknown and go undetected or untreated. The establishment of an “Obstructive Sleep Apnea 
Death and Near Miss Registry” by the Society of Anesthesia and Sleep Medicine and the 
Anesthesia Closed Claims Project is a step towards addressing these concerns (Biddle et al., 
2016). The objectives of the “Obstructive Sleep Apnea Death and Near Miss Registry” are to 
help determine the level of monitoring at the time of death or near-miss and describe why the 
adverse event happened to provide understanding of how best to study the phenomena (Biddle et 
al., 2016). What occurs during the first 24 to 48 hours subsequent to same-day ASC surgery? 
This literature review aims to show the inherent gaps as well as identify what may be known 
about ambulatory surgery patients with OSA after they are released to their homes. The goal is to 
show the need for a study intended to answer questions aimed at improving patient safety and 
minimizing risks and adverse outcomes in the postoperative period.  
In this chapter sleep apnea is defined before introducing the magnitude of the patient 
safety problem of OSA in the general population and the impact this phenomenon has on 
cardiopulmonary postoperative risks in the general surgical population. The chapter focuses on 
these same risks as it affects the ambulatory surgery patient population. The chapter ends with a 
summary. 
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Obstructive Sleep Apnea and the Surgical Patient 
ASCs offer patients the convenience of having surgeries and procedures performed safely 
outside a hospital setting. Endoscopic procedures are the largest driver of ASC growth 
accounting for 32% of Medicare payments (Koenig, Doherty, Dreyfus, & Xanthopaulos, 2009). 
In spite of the increase in number of ambulatory cases, adverse events are less than 1% and 
major morbidity occurs with a frequency of approximately 0.1% (Kent et al., 2014). 
Notwithstanding, as more Americans living with OSA receive ambulatory surgery, the likelihood 
of increased postoperative morbidity and mortality is real. 
OSA is one of several comorbidities that affect and is more prevalent in the surgery 
population, which is more than the general population and puts patients at increased risk for 
cardiopulmonary, neurocognitive, psychiatric, and gastrointestinal disorders, postoperative 
complications, morbidity, and mortality (Ambrosii, Sandru, & Belii, 2016; Chiang et al., 2017; 
Nagappa et al., 2017). The outpatient surgery population is particularly vulnerable, because 
patients arrive with undiagnosed OSA and go home unmonitored after the immediate 
postoperative/recovery period. In fact, a recent retrospective study showed that outpatients who 
were determined to have OSA during their preoperative visit had more respiratory complications 
than patients with known OSA (Fernandez-Bustamante et al., 2017). Fernandez-Bustamante et 
al. (2017) did not address cardiovascular complications in their study. An estimated 26% (25 
million) of Americans between the ages of 30 and 70 have sleep apnea (Peppard et al., 2013). 
The incidence of undiagnosed OSA in patients undergoing endoscopy procedures is 40 to 43% 
(Boese et al., 2014).  
Patients with hypertension have a higher rate of screening positively for OSA (70%) than 
those without hypertension (20%; Ge et al.,2013). Severe untreated OSA has been associated 
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with increased all-cause and cardiovascular mortality (Fu et al., 2017; Wang et al., 2013). OSA 
continues to be a common medical condition (Peppard et al., 2013) and is an important risk 
factor for SCD (Gami et al., 2013). Nocturnal hypoxemia is an important pathophysiological 
feature of OSA and strongly predicted SCD independently of well-established risk factors (Gami 
et al., 2013). In a meta-analysis, Iftikhar, Valentine, and Bittencourt (2014) found a favorable 
reduction of blood pressure with implementation of CPAP treatment in patients with recalcitrant 
hypertension and sleep apnea. In another published study, Cintra, Leite, and Storti (2014) found 
that nocturnal cardiac arrhythmias occurred in 92% of patients with severe sleep apnea compared 
to 53% of people without sleep apnea. The prevalence of circadian rhythm disturbance also 
increased with the severity of sleep apnea (Cintra et al., 2014). 
The obesity epidemic and its associated co-morbidities, of which OSA is one, is likely to 
result in an increased number of patients who arrive in outpatient centers for screening and 
diagnostic endoscopies. Screening referrals will increase even more, particularly since OSA 
patients are known to be at increased risk for cancers, including colorectal cancers (Fang, Miao, 
Chen, Sithole, & Chung, 2015; Lee et al., 2017).  So far, adverse events are rare (Rutter et al., 
2012; Stock et al., 2013), but as patients with multiple co-morbidities and more procedures 
continue to be performed at ambulatory centers, this may change. 
Sleep Apnea: Definition and Identification 
OSA is the most common sleep disorder (Garcha et al., 2013). OSA is characterized by 
frequent partial or complete collapse of the upper airway during sleep. This leads to decreased 
blood oxygen levels (desaturation), increased respiratory effort, arousal, and sleep disruption. 
Patients will typically present with witnessed apneic periods, loud snoring, and excessive 
daytime somnolence. Hyper-somnolence resulting from fragmented sleep can increase 
  
18 
 
probability of motor vehicle and other accidents, as well as decreased quality of life (Garcha et 
al., 2013). 
The Apnea-Hypopnea Index (AHI) is the measure used to delineate the severity of OSA. 
Sleep apnea is rated as mild, moderate, or severe (Joshi et al. 2012). Mild is an AHI of -5 to 15 
events per hour of sleep; moderate is -15 to 30 events per hour; severe is more than 30 events per 
hour of sleep (Joshi et al., 2012). Polysomnography is still considered the reference standard for 
diagnosing OSA. It is both time-consuming and expensive and must be performed in a sleep 
laboratory. In the pre-operative setting, the Society for Ambulatory Anesthesia Consensus 
recommended that the STOP-Bang Questionnaire be used as a screening tool to detect OSA 
based on its high sensitivity and construct validity. (Joshi et al., 2012).  
OSA is prevalent, though exact numbers are unknown, and is estimated to affect 10% to 
17% of the U.S. population and as many as 49% in those of advanced ages (Peppard et al., 
2013). That estimate is based on greater than or equal to 15 events/hour AHI. At greater than or 
equal to 5 events/hour AHI the overall population prevalence ranged from 9% to 38%. Among 
the elderly, prevalence was as high as 90% for men and 78% for women. Exact prevalence is 
undetermined partly because of variable criteria used to define disease, such as the number of 
apneic episodes per hour, or whether there are accompanying specific signs or symptoms 
(Senaratha et al., 2016; Young, Peppard, & Gottlieb, 2002).  
Sleep Apnea and Cardiopulmonary Risk in the Surgical Population 
OSA is associated with adverse physiological consequences, including cardiovascular 
disease, hypertension, cognitive impairment, and metabolic abnormalities, such as type 2 
diabetes; OSA is also associated with increased risk for postoperative cardiac and pulmonary 
complications (Garvey, Pengo, Drakatos, & Kent, 2015). Several comorbidities that are 
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frequently present in OSA patients reportedly result in higher mortality risks (Chiang et al., 
2017). Chiang et al. (2017) identified ten comorbidities that negatively impacted mortality of 
OSA patients. The top two were hypertension and chronic obstructive pulmonary disease, 
reflective of the negative impact OSA can have on cardiac and pulmonary physiology.  
Nagappa et al. (2017a) completed the first meta-regression analysis comparing the 
incidence of postoperative complications among surgical patients at high risk for OSA (HR-
OSA) versus those at low risk for OSA. From their systematic review they found a prevalence of 
33.3% HR-OSA in the surgical population. After non-cardiac surgical procedures, adverse 
cardiopulmonary events were two to three times higher in OSA versus non-OSA patients, and in 
patients with HR-OSA cardiopulmonary risk was as much as four times higher. There was also 
an accompanying two-day increase in length of hospital stay. The authors felt that their analysis 
supports the use of the STOP-Bang questionnaire as a perioperative risk stratification tool to 
identify HR-OSA patients. 
The strong association between arterial hypertension and OSA has been extensively 
described, studied, and established (Mohsenin, 2014; Parati, Ochoa, Bilo, & Al, 2014). 
Hypertension is common among OSA patients (35 to 80% affected) and appears to be directly 
affected by OSA severity. Conversely, among hypertensive patients the percentages affected by 
OSA range from approximately 40 to 50% (Parati et al., 2013). Moderate to severe OSA (AHI 
15 to greater than 30 events per hour) is associated with a greater overall risk for cardiovascular 
diseases. These cardiovascular diseases include hypertension, coronary artery disease, stroke, 
congestive heart failure, and atrial fibrillation (Wang et al., 2013). 
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Sleep Apnea and Cardiopulmonary Risk in the Outpatient Surgery Population 
OSA is particularly prevalent in the outpatient surgery population with as many as one 
fourth of patients undergoing elective surgery affected (Wolfe, Pomerantz, Miller, Weiss-
Coleman, & Solomonides, 2016). GI endoscopies are known to be the most frequently preformed 
outpatient procedure, and patients who need gastrointestinal endoscopies also commonly have 
OSA (Chien et al., 2015). 
While it is known that OSA negatively impacts postoperative outcomes, there are very 
few published studies that bear this out. Memtsoudis and Stundner (2014) analyzed data on over 
500,000 hip and knee arthroplasty patients from over 400 institutions. These authors found that 
OSA was associated with a 47% increased risk of postoperative major morbidity and increased 
utilization of resources and length of stay (LOS). More recently, Ambrosii, Sandru, and Belii 
(2016) conducted a prospective descriptive study in Romania that enrolled 400 patients and 
reported that patients with OSA had 87.3% of postoperative complications and adverse events 
compared to 12.6% for those without OSA. Additionally, a retrospective cohort analysis of 418 
patients who had undergone outpatient colonoscopy was done to assess the association of BMI 
and cardiopulmonary adverse events  for ambulatory colonoscopy (Patel, Romain, Sanchez, 
Fisher, & Schulteis, 2017). This study was important because it showed OSA to be an 
independent risk factor for CAEs, independent of BMI and type or degree of sedation. 
Obstructive Sleep Apnea and Patient Safety 
Reason (2000) studied error management in clinical settings. The SCM was developed 
from Reason’s studies and that holds that most errors or accidents are caused not so much by 
unavoidable human error, but rather by an organization’s inadequate layers of error protection 
that allow errors to pass through unchecked on their way to causing harm. These layers of 
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protection are like slices of Swiss cheese with gaps that may allow errors to pass through 
unchecked on their way to causing harm. 
The holes in the SCM represent deficiencies in organizational defenses. Unlike holes in 
real Swiss cheese, these holes are dynamic. They open, close, and change location over time. 
Holes in these layers of protection happen for two reasons: active failures and latent conditions. 
Latent conditions may allow holes to align and permit a trajectory of accident opportunity 
bringing hazard or harm to the patient or system. The trajectory path ultimately shows that errors 
result from holes in multiple layers of safeguards.  
As many as 25% of patients undergoing surgery have OSA, but few hospitals or ASCs 
have policies that address the risks of this condition during the perioperative period, and fewer 
follow recommended consensus statements (Joshi et al., 2012). How patients with OSA are 
identified, determined suitable for ambulatory surgery, and discharged after ambulatory surgery 
represents a trajectory of problems inherent within the system that bring harm to patients. Not 
considering the needs of patients with OSA in ASC settings and the possible associated cardiac 
sequelae represents a latent risk factor that was mitigated by information generated by this study.  
The study is innovative not only because of the use of three wearable body sensors, one 
of which utilizes Bluetooth technology and near real-time monitoring, but because to date, none 
have reported the clinical and ECG risk factors of cardiac risks that occur in this group of 
patients, particularly in the 24 hours immediately following discharge from ambulatory surgery 
(Rotenberg, 2013). Amidst this dearth of scientific evidence, organizations concerned with 
patient safety such as the American Society of Anesthesiologists, have recommended that 
patients with OSA be observed for extended periods of time and routinely receive CPAP; Joshi 
et al., (2012). Some institutions require that certain populations of patients with OSA who have 
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received particular narcotics be held overnight and not undergo surgery in ASCs (Rotenberg, 
2013). Health care providers are rightfully concerned about the increased risk of adverse events 
for OSA patients. These measures may prove to be unnecessary and are inconsistently practiced 
(Memtsoudis & Stundner, 2014). More studies are needed to better identify patients who are at 
risk and apply evidence-based interventions that will significantly improve and impact outcomes 
and influence appropriate protocols to properly and efficiently manage these patients. 
Summary 
Based on the review of the literature, there has not been a study that has quantified both 
the cardiac and pulmonary risk factors that either ambulatory surgical patients or ambulatory 
patients undergoing endoscopies may be susceptible to in the immediate postoperative period (24 
hours post procedure). The study was, therefore, designed to examine the prevalence of patient 
and procedural risk factors for adverse cardiopulmonary events in patients presenting for 
outpatient endoscopy under deep Propofol sedation and to determine the relative risk of adverse 
cardiopulmonary events occurring in the first 24 hours at home in patients with and without 
OSA. The following chapter sets forth the methodology of the study. 
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Chapter 3: Methodology 
 
 
Research Design  
The study utilized a prospective, descriptive cross-sectional design and incorporated a 
pre-test/post-test data collection approach. There was no manipulation of the independent 
variable, operationalized as the presence or absence of OSA. This was coded as ‘0’ indicating 
absence of OSA and ‘1’ presence of OSA. Presence of OSA was assessed based upon a STOP-
BANG (Snoring, Tired, Observed, Pressure, Body Mass Index, Age >50, Neck Size,             
Gender = male) score greater than 3. The STOP-BANG is widely recognized as a reliable and 
valid inventory for OSA and is widely used in both clinical research and clinical practice 
domains (Cowan et al., 2014). The study had components of both a descriptive and a non-
randomized pre- and post-test design.  
This study is objective and quantitative because the data yielded quantifiable answers to 
closed-ended research questions. The equipment used to gather the data provided numerical data 
only. Regression analyses, t-test analyses, and ANOVAs were the primary statistical methods 
used. 
This is a descriptive study because it aims to discover what are the cardiopulmonary risks 
of outpatients with and without sleep apnea. It is also cross-sectional because it examined the 
relationship between OSA, ambulatory surgery, and cardiopulmonary risk factors as delineated 
in Table 1 (page 9). 
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Selection of Subjects 
The target population for the study consisted of outpatients scheduled for endoscopy, 
recruited through the selected facility. Approximately 25,000 patients receive endoscopies at the 
facility on a yearly basis, so enrollment of patients in using the facility was more efficient than 
most other centers. The researcher recruited a convenience sample of participants to address the 
research questions related to the prevalence of clinical and ECG cardiac risk factors of cardiac 
risk in post-endoscopy outpatients with and without OSA. A convenience sampling approach 
was appropriate because the researcher maintains a relationship with the doctors and staff of the 
facility, and the researcher recruited participants who were easily accessible via the facility 
(Acharya, Prakash, Saxena, & Nigam, 2013). A convenience sampling approach is best suited for 
the study because it would be difficult to include a randomized sample of participants from the 
target population (Etikan, Musa, & Alkassim, 2016).   
  Eligible participants were at least 18 years of age or older and scheduled to receive 
sedation for endoscopy at the certified and credentialed endoscopy center. Participants were able 
to independently review and complete the informed consent to participate in the study. Eligible 
participants were fluent in either English or Spanish.  
The final target sample was comprised of 50 adults scheduled to receive sedation for 
endoscopic procedures at the ASC site. The center provides screening, detection, and polyp 
removal for approximately 80 patients on a daily basis. Consequently, there was an adequate 
flow of subjects for study inclusion. Subjects were approached during pre-procedure office visits 
with their gastroenterologist. During the patients’ visits to the office, the principal investigator 
(PI) discussed the study protocol with the patient and determined if he or she would be interested 
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in consenting to participation in the study. The PI informed patients of the purpose of the study 
and of the follow-up requirement in case of a concerning adverse event. 
 Eligible subjects were recruited from the endoscopy schedule 30 days prior to the 
procedure up to two days preceding the procedure. The pre-anesthesia assessment was 
completed, updated, or revised on the day of the procedure, as is standard and mandated 
anesthesia practice. The ASC serves a diverse population and ensured an ethnically and 
culturally diverse patient pool for recruitment.  Because Holter monitors and pulse oximeters 
must be returned and disinfected prior to use on subsequent subjects, the return of equipment 
limited the speed of recruitment. Given the anticipated three-day turnaround time for equipment, 
subjects generally received monitors on Mondays and Thursdays. The budget for the project 
included rental of 6 BodyGuardian cardiac monitors, 10 pulse oximeters, and rental of 10 
MicroMotionlogger Actigraph watches. Figure 1 illustrates the schedule of activities for the 
study. 
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Figure 1. Study chronology 
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Study participants were assigned to one of three groups based on their STOP-BANG 
scores and presence or absence of previous diagnosis of sleep apnea as follows: probability of 
moderate to severe OSA (previously undiagnosed and untreated or diagnosed with treatment) or 
low-risk OSA (no OSA) groups based on their STOP-BANG scores. A STOP-BANG score 
greater than or equal to 3 is considered moderate to high risk for OSA (Table 2). 
Table 2: STOP-BANG Grouping  
Group Score Diagnosis 
1 <3 Low risk or no OSA 
2 ≥3 
Moderate to severe OSA 
(previously undiagnosed and 
untreated) 
3 ≥3  
Moderate to severe OSA 
(diagnosed with treatment) 
 
Recruitment continued until 51subjects proceeded through enrollment and data 
collection. One subject was removed because of incomplete data for a final count of 50 subjects. 
Enrollment took place over a 4-month period. Power analyses were conducted for the regression 
analysis using the number of times that an individual’s SpO2 level dropped below 90 (red) and 
the duration of time that an individual spent with an SpO2 level below 90 (blue) on the STOP-
BANG measure. There are 11 dependent variables; of these 11 variables, two variables have 
prototypical large and small expected effect sizes. The other 9 dependent variables fell 
somewhere between these two extremes. The power of the STOP-BANG procedure to predict 
number of significant SpO2 events is much larger than the power of the STOP-Bang procedure 
to predict the duration of time spent in an event. Specifically, approximately 50 patients are 
required to achieve 80% power to detect significant increases in the number of events associated 
with higher STOP-Bang measures, while approximately 150 patients are required to achieve 
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80% power to detect significant increases in the duration of such events. The strength of the 
associations was based upon preliminary analyses from another project (Biddle et al., 2016). As 
the current power analyses are a priori, it is possible that the associations observed are slightly 
larger or smaller. To account for this, the shaded areas of Figure 2 show the power for a 20% 
larger or smaller effect size. 
 
 
Figure 2. Power analysis for detection of number of events. 
 
Instrumentation 
The STOP-BANG Questionnaire, a validated and reliable predictor of obstructive events 
was used to classify subjects according to OSA risk (Cote et al., 2010; Cowan et al., 2014). For 
surgical patients, the STOP-BANG Questionnaire is recommended for OSA screening because 
of its ease of use and high degree of sensitivity. It is not feasible to have all patients undergo a 
  
29 
 
sleep study preoperatively. Screening questionnaires can successfully identify at-risk patients 
and allow the anesthesia provider to establish an early plan of care targeted at minimizing 
intraoperative/postoperative complications. 
The Respironics Nonin WristOx 3150 from Nonin Medical, Inc. Plymouth, MN is an 
U.S. Food and Drug Administration-approved pulse oximeter, designed to be worn comfortably 
on the patient’s wrist. It is well suited for in-home use and measures heart rate as well as arterial 
oxygen saturation (SpO2). The device is activated when the soft probe is capped over a fingertip. 
Sensitivity and negative likelihood ratio are reported at 100% and 0%, and specificity is of 
100%. NONIN(R) Wrist Ox(R) 3100, 2005; Society of Anesthesia and Sleep Medicine. The 
accuracy of the device is reported to be 70% to 100% SpO2 within +/- 2% SD and +3% for pulse 
rate, with a bias of +0.03 and precision of +/- 2.08 SD. The accompanying software (nVision) 
was used for analysis of the retrieved data. 
The 9 high-risk ECG parameters can be seen in Table 1 (page 9). This table was created 
based on a review of the literature to determine the appropriate ECG parameters used to assess 
cardiac risk (Carey & Thevenin, 2009). These ECG parameters were derived from parameters 
obtained using both a 12-lead ECG monitor before the procedure and the BodyGuardian cardiac 
monitor for continued monitoring after the procedure. The BodyGuardian by Preventice 
(Minneapolis, MN) is an FDA cleared device that is worn on the chest with the aid of bandage 
patch. This cardiac monitor uses Bluetooth technology to deliver biometric data (i.e., ECG, heart 
rate, activity level, and body position) securely to a smartphone which delivers the information to 
the cloud in real time using the Sprint network while meeting Health Insurance Portability and 
Accountability Act standards. 
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The Micro-Motionlogger is an Actigraph watch validated against polysomnography 
approved by the FDA for clinical research and use (Rupp & Balkin, 2011). The device has a tri-
axial digital micro-electromechanical system-based accelerometer that senses and measures 
gravitational changes. Utilization of tri-axial dimensions result in increased reliability and less 
variability between devices. The device is water-resistant, so it can be worn continuously for all 
types of activities. The accompanying Action4 software sports up to 28 parameters from the 
micro-motionlogger watch. This data provided information on sleep and non-parametric 
circadian rhythm parameters. 
Field Procedures 
Participants were required to sign an IRB-approved informed consent form prior to 
participation in the study. Documentation of the consent process was required including 
documentation that follow-up requirements were reviewed with each patient. Within the 30 days 
prior to the procedure, the investigator provided participants with written materials outlining the 
study’s purpose, expected participation, duration, foreseeable risks, discomforts or 
inconvenience, benefits of the research to society and the participant, and contact information for 
the person to contact regarding questions or in the event of a research-related injury or 
emergency. Pictures and written instructions for application and care of the monitors were also 
provided to participants. 
The investigator ensured that participants had sufficient time to review the material and 
ask questions before completing the informed consent. Participants were informed that their 
participation was voluntary and that refusal to participate would not result in any negative 
consequences or loss of benefits to which they are entitled. The informed consent also included a 
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statement regarding the participants’ right to confidentiality and right to withdraw from the study 
at any time without any consequences. 
Data Collection and Recording 
 Subjects were initially recruited during the office visit with the GI physician, Advanced 
Registered Nurse Practitioner, or Physician Assistant. They were screened for inclusion pending 
their expressed interest in participating in the study. Once the schedule was confirmed, which 
generally occurred three days prior to the procedure, subjects who met inclusion criteria were 
asked to return to the office to sign informed consent for the study. Following the consent 
process, participants picked up the MotionWatch-8, pulse oximetry, completed the pre-operative 
anesthesia assessment including the STOP-BANG, and had a baseline 12-lead ECG recording 
then or on the day of the procedure. The subjects also had the option of having the information 
packet (including the informed consent) sent electronically to allow enough time for review of 
the documents and to ask questions. The pre-anesthesia assessment on pick up day included the 
STOP-BANG Questionnaire for all the research participants. Enrolled participants were prepped 
for the procedure per the facility standard. On day 1, participants began wearing the Actigraphy 
watch which was to be worn continuously for a 3-day period. The Pulse Oximeter was worn 
during hours of sleep on the first night of the study as well as the 24-hour period after receiving 
anesthesia for the endoscopy (night three). 
 Subjects were re-assessed by the anesthesia team on the day of the procedure. The 
cardiac monitor was worn during the 24-hour period immediately after discharge from the 
recovery room on day three. On the fourth day all three monitors were either returned to the GI 
doctor’s office or pick up was arranged. Data was retrieved from the returned monitors once they 
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were returned. Monitors were cleaned, and batteries replaced if necessary. Monitors were then 
ready for assignment to subsequent participants.  
 The subjects were continuously monitored by a CRNA while receiving Propofol sedation 
during the endoscopy and up until transfer to the PACU. The patients were fitted with the cardiac 
monitor by a research team member when fully awake and deemed fit for discharge. The PI was 
available at all times for any concerns or questions participants had. All participants received a 
$25 gift card when the monitors were returned.  
Data Processing and Analysis 
Preliminary Data Management.  IBM SPSS version 24 was used for data management 
and analysis. The dataset was screened for outliers prior to data analysis. Standardized values 
were calculated for each continuous variable. Standardized values represent each data point’s 
distance from the sample mean (Tabachnick & Fidell, 2013). Standardized values greater than 
3.29 units from the sample mean were considered evidence of an outlying value (Stevens, 2009). 
Outliers, defined as greater than three standard deviations from the mean, were removed from the 
dataset so the data would not be skewed. 
Research Questions and Hypotheses.  RQ1: What is the prevalence of known ECG 
characteristics for cardiac events among pre-endoscopic patients with high and normal STOP-
bang scores on resting 12-lead ECGs clinical (pulse oximetry and actigraph derived sleep quality 
scores) and ECG characteristics of cardiopulmonary risk in post-endoscopy outpatients with 
undiagnosed or untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and 
post-endoscopy patients without OSA? 
RQ2: Among post-endoscopic patients receiving propofol, using a rhythm event recorder 
(BodyGuardian Heart) are there statistically significant differences in the frequency of oxygen 
  
33 
 
desaturation events and tachy-brady-arrhythmias over 24 hours between outpatients with 
undiagnosed or untreated OSA, and post-endoscopy patients with and without a medical 
diagnosis of OSA? 
RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG, 
are there statistically significant differences in the duration of resting heart rate, QRS duration, 
QTC duration and ST segment deviation between patients with low and high STOP BANG?  
RQ4: Does sleep quality influence pulse oximetry readings? The variables included in the 
study for Research Question 1 are clinical (pulse oximetry and Actigraph derived sleep quality 
scores) and ECG risk factors of cardiac risk (Table 1). For Research Question 2, the dependent 
variables are ECG and pulse oximetry. These dependent variables were compared among three 
groups of participants: post-endoscopy outpatients with undiagnosed or untreated OSA, post-
endoscopy outpatients receiving treatment for OSA, and post-endoscopy patients without OSA. 
The predictor variables for Research Question 3 are the comorbidities participants experience: 
diabetes, hypertension, obesity, OSA. The criterion variable is the number of adverse events 
participants experienced during the study. For Research Questions 4, the variables of interest are 
sleep quality, number of adverse events, and pulse oximetry readings.  
Statistical Analyses 
Descriptive Statistics.  The researcher conducted descriptive statistics to address 
Research Question 1. Descriptive statistics to represent the prevalence of clinical (pulse oximetry 
and actigraph derived sleep quality scores), ECG risk factors and participant group: post-
endoscopy outpatients with undiagnosed or untreated OSA, post-endoscopy outpatients receiving 
treatment for OSA, and post-endoscopy patients without OSA. Frequencies and percentages 
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were calculated for any categorical variables in the dataset (Howell, 2013). Means and standard 
deviations were calculated for any continuous variables in the dataset (Howell).  
Analysis of Variance (ANOVA).  The researcher conducted ANOVAs for Research 
Question 2 and 3. ANOVAs are the appropriate analysis to conduct when the researcher intends 
to assess mean differences between more than two groups (Field, 2013). The independent 
variables for the analyses are patient group (operationalized as post-endoscopy outpatients with 
undiagnosed or untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and 
post-endoscopy patients without OSA) and sleep quality, operationalized as sleep efficiency 
measure from the Actigraph watch. The ANOVA allowed the researcher to assess statistically 
significant differences in the dependent variable by the groups corresponding to each 
independent variable (Pallant, 2013).  A Tukey post hoc analysis was conducted to determine 
where the statistically significant differences lie between groups (Pagano, 2010). An a priori 
alpha level has been set at .05. 
Multiple Linear Regressions.  For Research Question 4 the researcher conducted a 
multiple linear regression. Multiple linear regressions are appropriate for analysis of the 
predictive relationship between a set of predictor variables and a criterion variable (Pagano, 
2010). The researcher conducted multiple linear regressions to assess the predictive relationships 
between comorbidities and the number of adverse events participants experience. The researcher 
reported the F statistic and p value to indicate the statistical significance of the overall regression 
model (Pallant, 2013). The R2 was reported to represent the amount of variation in the criterion 
variable that can be attributed to the predictor variables (Field, 2013). An a priori alpha level has 
been set at .05. 
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Limitations 
The results must be viewed with respect to the study’s limitations. The study was 
conducted with patients receiving Propofol sedation for outpatient endoscopies. While 
surveillance occurred both 24 hours before and after the procedure, it is ideal to monitor for an 
additional 24hr period of time. These results cannot be translated to the general surgical 
population or all outpatients. 
Summary 
The methodology as set forth in this quantitative longitudinal pre/post study, utilizing 
four instruments (STOP-bang questionnaire, Pulse oximeter, Actigraph watch, cardiac monitor); 
aims to describe, identify and quantify cardiopulmonary risk factors for outpatients in the 24 
hours post endoscopy. The following chapter summarizes and present the collected data, 
statistical treatment and analysis of the data. 
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Chapter 4: Findings 
 
 
 The purpose of this study was to assess the prevalence of patient risk factors for 
cardiopulmonary adverse events in a diverse range of patients presenting for outpatient 
endoscopy under deep propofol sedation, and to determine the relative risk of adverse 
cardiopulmonary events occurring in the first 24-hours post-procedure following deep propofol 
sedation for endoscopy in patients with or without OSA 
Over 4 months, 51 outpatients were recruited and consented to participate in this research 
study. One was removed because of incomplete data set for a final count of 50 subjects. Most 
outpatients in the sample were women (n = 35, 70%) and most had colonoscopy procedures             
(n = 44, 86%). Thirty eight percent of the participants had a STOP-BANG score greater than 
three and were therefore categorized as likely to have sleep apnea. Nine participants (18%) had a 
medical diagnosis of OSA, seven (14%) of whom had a medical diagnosis of OSA and used 
home CPAP. Fifteen participants were hypertensive (30%; Table 3).  
Table 3:  Sample Characteristics, N = 50  
Characteristic N % 
Female 35 70 
Colonoscopy 44 86.3 
STOP-Bang Score ≥3 19 38 
Medical Diagnosis of Sleep Apnea 9 18 
Home CPAP 7 14 
Hypertensive (120/80 mmHg) 15 30 
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Table 4 presents frequencies and percentages for the number of participants presenting 
with sleep apnea according to their STOP-Bang scores. Scores lower than 3 on the STOP-Bang 
questionnaire are considered evidence that the participant is unlikely to have sleep apnea, while 
scores greater than or equal to 3 are likely indicative of sleep apnea. Participants with low risk of 
sleep apnea represented most of the sample (n = 31, 62%).  
 
Table 4: Frequencies and Percentages for Participants without Sleep Apnea (STOP-Bang ,3) 
and with Sleep Apnea (STOP-Bang ≥ 3), N = 50   
 N % 
 No 31 62 Yes 19 38 
 
 Table 5 presents frequencies and percentages for the number of participants who reported 
a medical diagnosis of sleep apnea. The majority of participants indicated that they did not have 
a medical diagnosis (n = 41, 82%).  
 
Table 5: Frequencies and Percentages for Participants Reporting a Medical Diagnosis of Sleep 
Apnea, N = 50  
 N % 
 No 41 82 Yes 9 18 
 
 
 Table 6 presents frequencies and percentages for participants exhibiting a fragmented 
QRS (fQRS) morphology and abnormality (notching and fragmentation) of QRS. A fQRS 
morphology was indicated by less than 2 R’ or notching in the nadir of the S wave with QRS less 
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than 120 or 2 R’ or notching in the nadir with wide QRS (Virk Hassan, Farooq, Ghani, & Arora, 
2016). The majority of the sample data indicated no fQRS morphology (n = 44, 88%). Most 
participants did not exhibit QRS abnormality (n = 32, 64%). 
 
Table 6 Frequencies and Percentages for Participants Exhibiting fQRS Morphology and 
Exhibiting QRS Abnormality, N = 50  
 N % 
fQRS Abnormality   
No 44 88 
Yes 6 12 
QRS Abnormality   
No 32 64 
Yes 18 36 
  
 Table 7 presents frequencies and percentages for presence of Premature Ventricular 
Contractions (PVCs) in participants. Almost all participants (n = 48, 96%) did not exhibit PVC. 
Table 7: Frequencies and Percentages for Presence of PVC in Participants, N = 50  
 N % 
 No 48 96 Yes  2 4 
 
 
 Table 8 presents frequencies and percentages for the presence of a depression or 
elevation of 1.00 mm in any of the leads. Most participants did not exhibit a depression or 
elevation of 1.00 mm in any of the leads (n = 40, 80%).  
Table 8: Frequencies and Percentages for Participants Exhibiting Depression or Elevation of 
1.00 mm in Leads  
 N % 
 No 40 80 Yes 10 20 
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 Table 9 presents descriptive statistics for participants’ age, STOP-Bang Score, and heart 
rate measures. The average of participants was 54.48 (SD = 12.34). STOP-Bang scores ranged 
from zero to six with an average of 2.24 (SD = 1.42). The average heart rate for participants was 
72.16 (SD = 11.32) and the average QRS duration was 86.66 (SD = 17.22). Finally, the mean 
QTc interval was 431.10 (SD = 30.40) and the mean ST segment in V1 was 139.40 (SD = 41.82). 
 
Table 9: Descriptive Statistics for Participants’ Age STOP-Bang Score, and Heart Rate 
Measures  
 Minimum Maximum M SD 
Age 30 83 54.48 12.34 
STOP-BANG Score  0  6  2.24  1.42 
Heart Rate- mean R-R intervals for all QRS 
complexes during the duration of the recordings 
50 102 72.16 11.32 
QRS duration- mean QRS duration on standard 
12 lead ECG 
45 145 86.66 17.22 
QTc interval per Bazett- Mean QRS onset to T 
offset interval of all leads 
363 537 431.10 30.40 
ST segment in V4 80 320 139.40 41.82 
 
Pre-Procedure 12-Lead ECG Analysis  
RQ1: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG, 
what were the baseline ECG risk factors for cardiovascular events present in the recording? All 
subjects were in the cardiac rhythm of normal sinus. The most prevalent ECG risk factor of 
cardiac events were notched QRS complexes which is a marker for ventricular scarring (Virk 
Hassan, Farooq, Ghani, & Arora, 2016). Nearly a quarter (n = 10, 20%) had ST segment 
deviation on the pre-procedure 12-lead ECG indicating possible myocardial ischemic or reduced 
coronary perfusion (Carey, 2016). Table 10 presents frequencies and percentages for aberrant 
ECG characteristics.  
  
40 
 
Table 10: Aberrant ECG Characteristics  
 N % 
Premature Ventricular Contraction (PVC) 2 4 
Left Ventricular Hypertrophy (LVH) 4 8 
Notched QRS complex  18 36 
Fragmented QRS (fQRS) 6 12 
ST segment event  10 20 
 
 Table 11 shows that the resting heart rates were normal and neither bradycardic or 
tachycardic. On average the other measures of duration, QRSd and QTc were normal as well as 
the magnitude of the ST segment.  
Table 11: Normal ECG Characteristics  
 M SD 
Resting Heart Rate (beats per minute) 72 11 
QRS Duration (milliseconds) 87 17 
QTc duration (milliseconds)  431 30 
ST segment deviation (millimeters) 139 42 
 
 
Post-Procedure Event Recorder Analysis  
 Regarding the rhythm event recorder worn for 24 hours, the mean heart rate was 78.14 
(SD = 11.05). Mean tachycardic, or fast, heart rate maximum was 114, with a mean of 91.35      
(SD = 37.19). The mean bradycardic, or low, heart rate ranged from 50 to 78, with a mean of 
38.33 (SD = 27.62). Table 12 presents 24-hour heart rate information for participants. 
Table 12: 24-hour Mean Heart Rate Data for Participants  
 Minimum Maximum Mean SD 
Overall heart rate 58 103 78.14 11.05 
Tachycardic heart rate 99 114 91.35 37.19 
Bradycardic heart rate 50 78 38.33 27.62 
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RQ2: Among post-endoscopic patients receiving propofol, using an event recorder, are 
there statistically significant differences in the frequency of tachy- and brady- arrhythmias over 
24 hours between outpatients with no diagnosis of OSA and a STOP-BANG score less than 3, 
outpatients with untreated OSA, and outpatients with a medical diagnosis?  
 A one-way ANOVA was conducted between three groups of participants: participants 
with no diagnosis of OSA and a STOP-BANG score less than 3 (Group 1); participants with 
untreated OSA (Group 2); and participants with a medical diagnosis (Group 3). The frequency of 
tachy-arrhythmias and brady-arrhythmias among those three groups was compared. Tables 13 
and 14 present descriptive statistics for the three groups of participants. 
Table 13:  Descriptive Statistics for Participants with No OSA, Untreated OSA, and a Medical 
Diagnosis of OSA, Tachycardia  
 
Group N M SD 
Std. 
Error 
95% C.I. for M 
Min Max Lower Upper 
Mean Tachy HR 
1 28 99.50 28.32 5.35 88.52 110.48 0 114 
2 13 79.31 46.06 12.78 51.47 107.14 0 111 
3 9 81.89 46.53 15.51 46.12 117.66 0 110 
Total 50 91.08 37.52 5.31 80.42 101.74 0 114 
% of time Tachy over 
24 hours 
1 28 11.25 13.30 2.51 6.09 16.41 0 50 
2 13 11.15 18.54 5.14 -.05 22.36 0 50 
3 9 6.78 7.00 2.33 1.40 12.16 0 20 
Total 50 10.42 13.88 1.96 6.48 14.36 0 50 
Length of longest 
uninterrupted Tachy 
episode in Minutes 
1 28 27.399 43.49 8.22 10.53 44.25 .00 209.59 
2 13 30.10 60.82 16.87 -6.65 66.85 .00 194.43 
3 9 22.47 29.86 9.95 -0.48 45.43 .00 84.48 
Total 50 27.21 45.83 6.48 14.19 40.23 .00 209.59 
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Table 14:  Descriptive Statistics for Participants with No OSA, Untreated OSA, and a Medical 
Diagnosis of OSA, Bradycardia 
 Group N M SD 
Std. 
Error 
95% C.I. for M 
Min Max Lower Upper 
Mean Brady HR 
1 28 37.61 28.87 5.46 26.41 48.80 0 78 
2 13 34.08 28.15 7.81 17.07 51.09 0 58 
3   9 44.67 25.42 8.47 25.13 64.21 0 61 
Total 50 37.96 27.77 3.93 30.07 45.85 0 78 
% of time Brady over 
24 hours 
1 28 5.97 9.16 1.73 2.41 9.52 0 35 
2 13 14.62 21.26 5.90 1.77 27.46 0 56 
3   9 10.00 15.92 5.31 -2.24 22.24 0 48 
Total 50 8.94 14.56 2.06 4.80 13.08 0 56 
Length of longest 
uninterrupted brady 
event in Minutes 
1 28 11.97 19.75 3.73 4.31 19.63 .00 71.20 
2 13 14.55 19.72 5.47 2.63 26.46 .00 58.17 
3   9 13.57 19.65 6.55 -1.54 28.67 .00 51.09 
Total 50 12.93 19.35 2.74 7.43 18.43 .00 71.20 
  
The results of the ANOVAs comparing the frequencies of tachy- and brady-arrhythmias 
between the three groups were not statistically significant (Table 15). These findings indicate 
that the frequencies of tachy-and brady-arrhythmias were similar across the three groups of 
participants. Because there were no statistically significant findings no post hoc testing was 
conducted. 
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Table 15:  Results of the ANOVAs Comparing Frequencies of Tachy- and Brady-arrhythmias 
Between the Three Groups of Participants 
 Sum of 
Squares 
df Mean 
Square 
F p 
Mean Tachy HR 
Between 4547.02 2 2273.51 1.66 .201 
Within 64432.66 47 1370.91   
Total 68979.68 49    
% of time Tachy over 
24 hours 
Between 145.68 2 72.84 0.37 .694 
Within 9292.50 47 197.71   
Total 9438.18 49    
Length of longest 
uninterrupted Tachy 
episode in Minutes 
Between 311.26 2 155.63 0.07 .931 
Within 102587.60 47 2182.72   
Total 102898.86 49    
Mean Brady HR 
Between 604.32 2 302.16 0.38 .685 
Within 37177.60 47 791.01   
Total 37781.92 49    
% of time Brady over 
24 hours 
Between 676.30 2 338.15 1.64 .206 
Within 9717.25 47 206.75   
Total 10393.56 49    
Length of longest 
uninterrupted brady 
event in Minutes 
Between 63.35 2 31.68 0.08 .922 
Within 18284.16 47 389.03   
Total 18347.51 49    
 
RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG, 
are there statistically significant differences in the duration of resting heart rate, QRS duration, 
QTC duration and ST segment deviation between patients with low and high STOP BANG?  
 Table 16 presents mean differences and p-values for comparison of ECG measures for 
high and low STOP-Bang groups. The t-test showed that across all ECG measures there were no 
statistically significant differences in mean ECG measure values across the two groups. All the 
p-values exceeded .05, therefore the researcher failed to reject the null hypothesis.  
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Table 16: Comparison of Means between Patients with High and Low STOP-BANG (Low < 3, 
High ≥ 3) 
ECG Measure Mean Difference p-value 
Resting HR (beats per minute) 2.7 0.415 
QRS duration (milliseconds)  -4.7 0.353 
QTc (milliseconds) 0.925 0.918 
ST segment (millimeters) 14.3 0.244 
 
RQ4: Does sleep quality influence pulse oximetry readings? Table 17 presents the results 
of the regression analyses conducted to assess the relationship between sleep quality and pulse 
oximetry readings. Statistical significance was found across several of the variables; however, 
the predictors accounted for minimal variation in the criterion variables. 
 
Table 17: Results of the Regressions for Duration and SEFF  
Variables df1 df2 F p R2 
Duration 
D0.sleeptime ~ duration.2 1 32 4.92 0.03 0.11 
Dn1.spo2_90 ~ duration.3 1 31 4.90 0.03 0.11 
AVEn1_spo290 ~ duration.3 1 31 6.78 0.01 0.15 
AVEd0_spo290 ~ duration.3 1 32 4.96 0.03 0.11 
AVEd1_spo290 ~ duration.3 1 12 5.42 0.04 0.25 
SEFF      
D0.sleeptime ~ seff.2 1 32 10.02 0.00 0.21 
D1.sleeptime ~ seff.2 1 12 8.52 0.01 0.37 
seff.3 ~ ASA Class 1 48 5.18 0.03 0.08 
dn2.spo2_90 ~ seff.3 1 25 4.33 0.05 0.11 
AVEn2_spo290 ~ seff.3 1 25 5.39 0.03 0.14 
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Chapter 5: Discussion 
 
 
 OSA is a disorder characterized by the intermittent cessation of breathing for at least 10 
seconds while the affected person sleeps (Garcha et al., 2013). OSA is a prevalent public health 
concern affecting approximately 22 million Americans (Parati et al., 2014). The present study is 
important because it is estimated that 80% of the population with OSA is undiagnosed, and many 
patients with OSA remain undiagnosed at the time of surgery (Parati et al., 2014). Singh et al. 
(2013) reported that surgeons and anesthetists failed to identify up to 58% of surgical patients 
who had OSA as confirmed by polysomnography. OSA increases the mortality and morbidity of 
patients requiring general anesthesia, sedation, or intravenous opioids, increasing their risk for 
perioperative complications as much as four times that of patients without OSA (Kaw et al., 
2012).  
The purpose of this quantitative cross sectional pre/post study was to evaluate the 
prevalence of cardiopulmonary risk factors among post-endoscopic patients with diagnosed and 
undiagnosed sleep apnea in the 24-hour period after surgery. This chapter includes a discussion 
of the results obtained from the cardiac, pulse oximetry, and Actigraphy devices worn by 
participants. The chapter also includes a discussion of the implications of the results for 
perioperative teams in positively impacting outpatient safety during the perioperative period. The 
chapter concludes with a discussion of implications for practice, recommendations for future 
research, and a summary. 
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 The research questions were: RQ1: What is the prevalence of known ECG characteristics 
for cardiac events among pre-endoscopic patients with high and normal STOP-bang scores on 
resting 12-lead ECGs, clinical (pulse oximetry and Actigraphy derived sleep quality scores) and 
ECG characteristics of cardiopulmonary risk in post-endoscopy outpatients with undiagnosed or 
untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and post-endoscopy 
patients without OSA? 
Notched QRS complexes are a marker for ventricular scarring (Virk Hassan, Farooq, 
Ghani, & Arora, 2016) and were the most prevalent ECG risk factor of cardiac events. 
Additionally, 20% (n=10) had ST segment deviation on the pre-procedure 12-lead ECG 
indicating possible myocardial ischemic or reduced coronary perfusion (Carey, 2016)Table 9. 
Pulse oximetry and actigraph derived sleep quality scores revealed no difference based on OSA. 
 RQ2: Among post-endoscopic patients receiving propofol, using a rhythm event recorder 
(BodyGuardian Heart) are there statistically significant differences in the frequency of oxygen 
desaturation events and tachy-brady-arrhythmias over 24 hours between outpatients with 
undiagnosed or untreated OSA, and post-endoscopy patients with and without a medical 
diagnosis of OSA? 
ANOVA results comparing the frequencies of tachy- and brady-arrhythmias between the 
three groups were not statistically significant (Table 11). Lack of significance means that 
frequencies of tachy-and brady-arrhythmias were similar across the three groups of participants. 
The ANOVA for oxygen desaturation events and sleep quality indices similarly reflected no 
differences across the three groups. 
RQ3: Among pre-endoscopic patients receiving propofol, using a resting 12-lead ECG, 
are there statistically significant differences in the duration of resting heart rate, QRS duration, 
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QTC duration and ST segment deviation between patients with low and high STOP BANG? The 
t-test for sleep quality indices reflected no differences between low and high STOP-bang groups. 
The presence or absence of OSA had no effect across groups on desaturation events or frequency 
of tachy-brady arrhythmias. Sleep quality also had no measurable influence on adverse events 
and was similar across all three groups, although participants diagnosed with OSA slept 
significantly longer than those in the untreated or no OSA group. 
 RQ4: Does sleep quality influence pulse oximetry readings? The regressions for sleep 
quality indices similarly reflected no differences between the three groups. 
Conclusions 
 The study described the prevalence of known ECG characteristics for cardiac events 
among pre-endoscopic patients with high and normal STOP-bang scores on resting 12-lead 
ECGs, clinical (pulse oximetry and actigraph derived sleep quality scores) and ECG 
characteristics of cardiopulmonary risk in post-endoscopy outpatients with undiagnosed or 
untreated OSA, post-endoscopy outpatients receiving treatment for OSA, and post-endoscopy 
patients without OSA. The statistical level of significance expected for adverse events (oxygen 
desaturation and tachy-brady-arrhythmias) occurring in either of the groups in the 24 hours after 
the procedure was not achieved. Notwithstanding, there was an interesting incidental finding. 
Approximately one quarter up to a third of the participants had ECG markers on their baseline 
12-lead that indicated decreased coronary perfusion, myocardial ischemia, or possible ventricular 
scarring. This is an unexpectedly interesting finding and latent hazard, given that no participants 
reported any previous significant cardiac event, nor did having these markers result in acute 
adverse events for the participants. In this sample, 20% of subjects (who would have otherwise 
been unidentified) without a medical diagnosis of OSA were identified as having undiagnosed 
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OSA based on STOP-bang scores. Pre-operative under diagnosis of OSA by anesthetists and 
surgeons represents one-way patients are exposed to avoidable risks. 
 While the results yielded no significant findings, several points are apparent. The 
importance of the preoperative anesthesia evaluation as a first line of defense against latent 
opportunities for hazard to become harm must be reiterated. In the Singh et al. (2013) study, 
almost 40% of patients with OSA confirmed by PSG only had one or two principal symptoms of 
OSA. At minimum, a proven screening tool like STOP-bang should be included as a requisite 
part of a thorough preoperative assessment.  
In addition to the STOP-bang survey, the opportunity exists to use inexpensive readily 
available tools such as ECG to minimize risk and optimize results for outpatients during the 
vulnerable perioperative period. One-third of the subjects in this study had ECG high-risk 
markers that indicated possible myocardial scarring or compromised coronary perfusion. Biteker, 
Duman, and Tekkesin (2011) studied the predictive value of the preoperative ECG for 
perioperative cardiovascular outcomes in patients undergoing noncardiac, nonvascular surgery. 
Based on their findings, Biteker et al. (2011) recommended that prolonged QTc be viewed as an 
independent marker for preoperative cardiovascular outcome after noncardiac, nonvascular 
surgery.  
While there was no significant instances of tachycardia or bradycardia post-procedure, 
the findings of these ECG markers highlight the role an individualized and complete 
preoperative assessment, that includes an ECG, can make towards thoughtful perioperative 
management and positive postoperative outcomes. The 12-lead ECG is inexpensive, convenient, 
and accessible to most outpatients. Although a pre-op ECG is not a current requirement for 
asymptomatic patients undergoing low-cardiac-risk surgery, individual patient factors such as an 
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above average BMI, having at least one risk factor for coronary artery disease, and consideration 
of OSA risk (assessed by STOP-BANG) should allow the ECG to be considered as part of an 
anesthesia pre-operative assessment. 
There was an instance where a participant with the medical diagnosis of OSA had a 
STOP Bang score of less than 3. The patient attributed consistent use of CPAP in improving 
blood glucose levels to where the patient was no longer diabetic or obese.  
Limitations 
This is the first study to monitor patients in their homes with cardiac, actigraphy, and 
pulse oximetry. It was a challenge ensuring compliance with all three devices. The patients were 
required to wear three separate monitors.  A heart monitor on the chest with an accompanying 
phone, an actigraphy watch on one wrist, and during sleep a pulse oximeter on the other wrist. 
One patient woke to find that all three monitors had been removed during sleep. Another patient 
went swimming in the watch and decided not to share that it quit working until the day of the 
procedure. Such issues with devices may have affected study results and partially explain 
findings of non-significance. The Bodyguardian with Bluetooth real-life monitoring was easiest 
to track, as the PI could check or allow notification in real time if the device was not being worn.  
 The sample size of 50 was the minimum needed to achieve 80% power to detect 
significant increases in the number of events associated with higher STOP-Bang measures. A 
larger, stratified sample of 150 or more may have improved statistical power. Examination of a 
power analysis graph indicated that increasing the number of participants did not greatly increase 
the statistical power of the analysis. The increase in statistical power from increasing the sample 
size did not justify the resource constraint (e.g., securing additional monitoring devices for 
additional participants) that would result from recruiting more participants. The researcher opted 
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to use a sample of 50 participants. The participants were only receiving propofol for endoscopy 
procedures. While this may be a strength in the uniformity of the drug received, the results may 
not generalize well to all outpatients who may receive general anesthesia or other classes of 
drugs (i.e., opioids, benzodiazepines, etc.) for other types of outpatient procedures. This study 
only included patients receiving sedation for endoscopy procedures that did not require post-
operative pain management and cannot be generalized to patients receiving general anesthesia 
who may require post-operative pain management and control. 
Implications for Practice 
Propofol anesthesia has taken the dread out of screening colonoscopies, resulting in an 
easier sale on the part of gastroenterologists encouraging patients to get screening colonoscopies. 
Anesthetists are often not included in the pre-operative evaluation of patients. This task is 
usually the job of the primary attending physician or specialist to whom the patient has been 
referred. Typically, anesthetists review the medical information on the day of the procedure, 
immediately preceding the patient’s entrance to the procedure room. On occasion, potential 
patient safety aberrancies are caught at the last moment and procedures are cancelled resulting in 
loss of time and revenue. The pressure is sometimes placed on the anesthetist to “just do the 
case” since, as evidenced by this study, patients often proceed through anesthetics without 
incident. The onus is on the anesthetist to place patient safety first. During the procedure, it may 
be noted that the patient may have OSA symptoms (i.e., an obstructed airway necessitating 
additional airway maneuvers) while under anesthesia. This is an opportunity for anesthetists to 
address the public health dilemma of undiagnosed OSA and help direct patients to appropriate 
resources for OSA screening. Pre-op clinics are not a reimbursable expense for insurance 
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purposes, but the payoff in perioperative patient safety and potential savings on public health 
costs would be well worth it. 
Outpatients go home unmonitored. This may not be considered serious after procedures 
that do not require pain medication during recovery, but for outpatient procedures such as 
bariatric and orthopedic surgery that may require pain control at home this becomes life 
threatening. Pain control at home combined with the current opioid crisis lends itself to yet 
another latent and potentially deadly hazard. The importance of recognizing OSA, signs of 
opioid abuse, and the utilization of anesthetic modalities that minimize and or eliminate narcotic 
use and overuse should be encouraged in a multidisciplinary approach. Patients identified as 
having OSA by STOP-bang should be referred for a sleep study to ensure pulmonary 
optimization before and after surgery. Noncompliant OSA patients who do not use CPAP should 
be counseled on the importance of using their equipment. Case in point was one patient in the 
study who converted to atrial fibrillation in the early morning after the procedure. The patient 
had fallen asleep without wearing CPAP. After a call from the company, the patient replaced the 
CPAP and spontaneously reverted to sinus rhythm.  
Similarly, patients with high-risk ECG markers signaling coronary perfusion issues or 
arrhythmia triggers may have their treatment customized to better ensure their safety during and 
after the procedure. Telemonitoring at home also could be made available when pertinent. The 
obligation should be on the perioperative team to ensure that during perioperative screening 
patients have the relevant equipment and that safety measures are anticipated and implemented.  
There is an opportunity for anesthetists to be important not only at the head of the OR 
table as clinicians, but as leaders in patient safety initiatives affecting public health, such as the 
opioid crisis and OSA, and even smoking cessation. Anesthetists should embrace the role of 
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patient safety advocate beyond the OR. Patients should be educated on the life-threatening 
physiological and quality of life consequences of not using CPAP when indicated. 
Recommendations for Future Research 
 This the first and only in-home study of utilizing three devices before and after surgical 
procedures. A pre- and post-test design was chosen for this longitudinal study to improve on a 
previous post-test study by Biddle et al. (2016) involving pulse oximetry monitoring of 
outpatients after orthopedic surgery. A convenience sample was used for this study for ease of 
recruitment and particularly because RQ1 was designed to identify the prevalence of known 
high-risk markers ECG characteristics in the outpatient endoscopy population. A Quota sampling 
technique would be helpful in future studies to hone in on the undiagnosed (high STOP-BANG 
score) OSA population. Further research might also include outpatient surgery populations that 
require general anesthesia and post-operative pain control. 
Future studies might use an integrated Bluetooth monitor with integrated features to help 
facilitate patient compliance. Spence, Han, Morrison, and Couture (2018) completed an in home 
prospective observational study of patients undergoing total joint arthroplasty. The researchers 
started out with one sleep monitor and switched to another sleep monitor mid study mainly 
because of patient complaints of how uncomfortable the first device was to wear.  The Watch-
PAT200 (Itamar Medical Ltd, Caesarea, Israel) the researchers eventually used to complete their 
study, is an FDA approved device that incorporates both pulse oximeter and Actigraph 
capabilities and could have reduced the device number to two versus three thereby helping 
enhance patient compliance. 
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Conclusion 
No differences were found between patients with and without OSA 24-hours post-
procedure following deep propofol sedation for endoscopy. The findings suggest that Propofol 
sedation may be safe for patients with OSA. Additionally, preoperative screening or post-
operative follow-up may not be necessary for Propofol sedation in patients with OSA, which can 
help to reduce healthcare costs. There were exactly enough patients to satisfy the power analysis 
with a sample size of 50, which was the minimum number needed to achieve 80% power to 
detect significant increases in the number of events associated with higher STOP-Bang 
measures. Findings should be interpreted with this limitation in mind, and replication of the 
study with a larger and stratified sample size is recommended. 
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Depiction of pulse oximeter 
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Depiction of micromotionlogger watch 
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Appendix B 
 
Stop-Bang Questionaire 
 
Depiction of Reason’s Swiss Cheese Model  
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Appendix C 
Spanish Informed Consent 
Información	relacionada	con	temas	de	la	investigación	y	formulario	de	
consentimiento		
Título:	Evaluación	de	de	la	base	de	referencia	y	los	factores	de	riesgo	después	de	
la	descarga	en	sujetos con	y	sin	apnea	del	sueño	que	se	someten	a	endoscopia	con	
sedación	profunda.	
NÚMERO	DEL	PROTOCOLO	DE	VCU	IRB:	HM20008241		
Patrocinador:	AANA	Foundation	(Fundación	de	AANA)		Si	existe	información	en	este	formulario	de	consentimiento	que	no	está	claro,		puede	pedirle	al	 personal	 del	 estudio	 que	 le	 explique	 cualquier	 información	 que	 	 no	 entienda	completamente.	 Puede	 discutir	 esto	 con	 su	 familia	 o	 amigos	 hoy,	 pero	 necesitamos	 que	firme	su	formulario	de	consentimiento	hoy	para	matricularse.	
	
PROPÓSITO	DEL	ESTUDIO	El	propósito	de	este	estudio	es	comparar	los	cambios	en	el	estado	de	los	sujetos	con	y	sin	apnea	del	sueño,	antes	y	después	de	la	sedación.		
DESCRIPCIÓN	DEL	ESTUDIO	Y	SU	PARTICIPACIÓN	Si	decide	participar	en	este	estudio	de	investigación,	se	le	pedirá	que	firme	este	formulario	de	consentimiento	después	de	haber	respondido	a	todas	sus	preguntas	y	entender	lo	que	le	sucederá.		Se	someterá	a	un	examen	físico	y	un	cuestionario	antes	de	la	cirugía	que	todos	los	pacientes	deben	 someterse	 antes	 de	 la	 cirugía.	 Le	 preguntaremos	 acerca	 de	 sus	 antecedentes	médicos	y	quirúrgicos,	medicamentos,	alergias,	revise	su	expediente	médico	completo.	Esta	información	 rutinaria	 también	 se	 utilizará	 en	 el	 estudio.	 Además	 de	 esta	 información	rutinaria,	 también	 se	 le	 harán	 preguntas	 para	 completar	 el	 cuestionario	 	 de	 STOP-BANG	(para	determinar	la	probabilidad	de	tener	la	apnea	del	sueño)	y	un	electrocardiograma	de	12	plomos	(ECG)	también	se	realizará	en	la	mañana	del	procedimiento.	Ambos	se	suman	a	su	 preparación	 preoperatoria	 habitual	 y	 son	 necesarios	 para	 las	 actividades	 de	investigación.		
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Si	 acepta	 este	 estudio,	 le	 pediremos	 que	 use	 un	 monitor	 cardíaco	 que	 es	 un	 tipo	 de	electrocardiograma	ambulatorio	 (ECG).	Este	dispositivo	registrará	 la	 actividad	eléctrica	de	 su	 corazón	 continuamente	 mientras	 se	 está	 moviendo	 durante	 sus	 actividades	habituales	 y	 durante	 el	 sueño.	 Se	 adjuntará	 con	 pequeñas	 almohadillas	 o	 parches	(electrodos)	 pegados	 en	 el	 pecho	 (ver	 demostración	 adjunta)	 después	 de	 su	procedimiento.	También	llevarás	un	reloj	de	movimiento	(como	Fitbit)	y	un	monitor	de	oxígeno	(mide	el	porcentaje	de	oxígeno	en	la	sangre)	antes	y	después	del	procedimiento.	El	 monitor	 de	 oxígeno	 sólo	 se	 llevará	 en	 la	 muñeca	 y	 el	 dedo	 (vea	 la	 demostración	adjunta)	siempre	que		descansa	o	duerme.		En	el	segundo	día,	devolverá	el	monitor	del	corazón,	el	reloj	de	movimiento	y	el	monitor	de	 oxígeno	 al	 equipo	 de	 investigación	 en	 el	 sobre	 de	 franqueo	 pagado	 que	 se	proporciona.	 Estará	 en	 un	 grupo	 de	 cerca	 de	 100	 otros	 pacientes	 de	 cirugía	 y	 su	información	permanecerá	confidencial.	Usará	el	reloj	del	movimiento	y	el	oxímetro	del	pulso	por	3	días	y	el	monitor	del	corazón	por	1	día.	Su	compromiso	de	tiempo	total	será	de	4	días.		
RIESGOS	Y	MOLESTIAS	Hay	un	riesgo	de	malestar	menor	cuando	se	usan	los	monitores,	especialmente	el	monitor	de	oxígeno.	Para	asegurar	 la	 comodidad,	 ajuste	 la	 correa	de	velcro	de	modo	que	no	esté	demasiado	apretada.			Puede	usarlo	en	 cualquiera	de	 las	muñecas.	También,	utilice	 la	punta	de	prueba	plástica	suave	del	dedo	en	cualquier	dedo	que		sienta	es	más	cómodo.	La	cinta	adhesiva	que	se	usa	para	 fijar	 los	 electrodos	 del	 monitor	 cardíaco	 debe	 ser	 removida	 cuidadosamente	 para	evitar	 la	 irritación	 de	 la	 piel.	 Vamos	 a	 hacer	 preguntas	 para	 completar	 el	 cuestionario	STOP-Bang	 y	 hacer	 un	 ECG	 de	 12	 plomos.	 Ambas	 actividades	 relacionadas	 con	 la	investigación	 no	 supondrán	 ningún	 riesgo	 adicional	 para	 	 y	 pueden	 proporcionar	información	adicional	importante	y	útil	a	los	médicos	que	proveen	su	cuidado.		Existe	 también	 un	 riesgo	 potencial	 de	 pérdida	 de	 confidencialidad.	 Este	 riesgo	 se	minimizará	 al	 almacenar	 su	 información	 de	 manera	 segura	 y	 de	 acuerdo	 con	 todas	 las	reglas	de	la	HIPAA	y	la	confidencialidad	de	la	investigación.			
USO	Y	DIVULGACIÓN	DE	INFORMACIÓN	PROTEGIDA	DE	SALUD		
Autoridad	para	Solicitar	Información	Protegida	de	Salud	Las	siguientes	personas	y	/	o	grupos	pueden	solicitar	mi	información	protegida	de	salud:	
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• Investigador	Principal	e	Investigación	 • Personal	del	Patrocinio	del	Estudio 
• Colaboradores	de	Investigación • Juntas	Institucionales	de	Evaluación	 
• Juntas	de	supervisión	de	seguridad	de	datos			 • Agencias	de	Gobierno	/	de	Salud 
• Otros	según	lo	requerido	por	la	ley  	
Autoridad	para	Divulgar	Información	Protegida	de	Salud		El	Baptist	Health	System	(BHS)	puede	divulgar	la	información	indicada	en	este	formulario	de	autorización	de	mi	antecedente	médico	para	proporcionar	esta	información	a:	
• Proveedores	de	atención	médica	de	BHS • Investigador	principal	y	personal	de	investigación 
• Proveedores	de	atención	médica	de	VCUHS • Colaboradores	de	Investigación 
• Coordinadores	de	datos • Juntas	Institucionales	de	Evaluación 
• Juntas	de	supervisión	de	seguridad	de	datos			 • Agencias	de	Gobierno	/	de	Salud 
• Otros	según	lo	requerido	por	la	ley • Patrocinador	del	Estudio 	Una	vez	que	su	información	de	salud	ha	sido	divulgada	a	alguien	fuera	de	este	estudio,	la	información	ya	no	puede	ser	protegida	bajo	esta	autorización.		
Tipo	de	información	que	se	puede	divulgar	Los	siguientes	tipos	de	información	se	pueden	ser	utilizados	para	la	realización	de	esta	investigación:	
• Antecedente	de	salud	completo • Resultados	de	las	pruebas	de	laboratorio 
• Historia	y	examen	físico • Informes	de	las	radiografías					 
• Informes	de	consulta • Información	del	abuso	de	drogas	o	alcohol 	
Caducidad	de	esta	autorización			
• Esta	autorización	expirará	cuando	se	cierre	el	estudio	de	investigación	o	no	sea	
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necesario	revisar,	analizar	y	considerar	los	datos	generados	por	el	proyecto	de	investigación,	lo	que	sea	posterior. 	
Derecho	a	revocar	la	autorización	y	la	Re-divulgación		Puede	cambiar	de	opinión	y	revocar	(retirar)	el	derecho	de	usar	su	información	protegida	de	 salud	 en	 cualquier	 momento.	 Aunque	 revoque	 esta	 Autorización,	 todavía	 los	investigadores	pueden	usar	o	divulgar	su	información	de	salud	que	ya	han	recopilado	para	este	 estudio.	 Si	 revoca	 esta	 Autorización,	 ya	 no	 podrá	 participar	 en	 el	 estudio	 de	investigación.	Para	revocar	esta	Autorización,	debe	escribir	al	Investigador	Principal.		
BENEFICIOS	PARA		Y	OTROS	No	puede	recibir	ningún	beneficio	directo	de	este	estudio.	Su	participación	puede	ayudar	a	su	equipo	de	atención	médica	para	identificar	a	los		pacientes	en	riesgo	de	eventos	futuros	cardiopulmonares	después	de	la	cirugía.				
COSTOS	No	hay	costos	por	su	participación	en	este	estudio,	excepto	por	su	tiempo	para	recuperar	y	usar	los	monitores	antes	y	después	del	procedimiento.		
PAGO	PARA	LA	PARTICIPACIÓN	Recibirá	una	tarjeta	de	regalo	Visa	de		$25.	Para	recibir	esta	tarjeta	de	regalo,	tiene	que	llevar	 los	 monitores	 el	 día	 antes	 y	 después	 del	 período	 de	 24	 horas	 después	 del	procedimiento.	 Debe	 enviar	 por	 correo	 los	monitores	 al	 equipo	 de	 investigación	 en	 el	sobre	 que	 se	 proporciona.	 Después	 de	 que	 el	 equipo	 de	 investigación	 reciba	 sus	monitores,	le	enviaremos	la	tarjeta	de	regalo	a	su	dirección	que		nos	proporcione.		
ALTERNATIVOS	Tiene	la	opción	de	no	participar	en	este	estudio.		
CONFIDENCIALIDAD	Su	 información	 potencialmente	 identificable	 consistirá	 en	 sus	 antecedentes	 médicos,	examen	 físico	 y	medidas	 de	monitoreo.	 Los	datos	 se	 están	 recopilando	sólo	 con	 fines	 de	investigación.		Sus	 datos	 serán	 identificados	 por	 un	 código	 numérico,	 no	 por	 nombres,	 y	 serán	archivados	en	un	programa	informático	protegido	por	 contraseña.	Toda	 la	 información	
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personal	 se	 guardará	 en	 archivos	 protegidos	 por	 contraseña	 y	 estos	 archivos	 se	eliminarán	al	final	del	estudio.	El	acceso	a	todos	los	datos	estará	limitado	al	personal	del	estudio.		Lo	que	encontramos	en	este	estudio	puede	ser	presentado	en	reuniones	o	publicado	en	artículos,	pero	su	nombre	no	se	usará	en	estas	presentaciones	o	artículos.		
PARTICIPACIÓN	VOLUNTARIA	Y	RETIRO		No	 tiene	 que	 participar	 en	 este	 estudio.	 Si	 decide	 participar,	 puede	 detenerse	 en	cualquier	momento	 sin	 ninguna	 penalización.	 También	 puede	 optar	 por	 no	 contestar	preguntas	particulares	que	se	hacen	en	el	estudio.		Su	participación	en	este	estudio	se	puede	ser	detenida	en	cualquier	momento	por	el	personal	del	 estudio	o	 el	 patrocinador	 sin	 su	 consentimiento.	 Las	 razones	 podrían	incluir:	• el	personal	del	estudio	piensa	que	puede	ser	necesario	para	su	salud	o	seguridad;	• no	cumplió	con	las	instrucciones	del	estudio.		• el	patrocinador	ha	detenido	el	estudio;	• o	motivos	administrativos	exigen	su	retiro.			Si	deja	el	estudio	antes	de	la	visita	final	programada,	devuelva	los	3	monitores	en	el	sobre	proporcionado.	No	recibirá	el	pago	por	la	participación	si	no	completa	completamente	el	monitoreo	durante	las	24	horas	completas	después	de	la	cirugía.				
CUESTIONES	Si	 tiene	 alguna	 pregunta,	 queja	 o	 inquietud	 con	 respecto	 a	 su	 participación	 en	 esta	investigación,	comuníquese	con:	
Mercedes	Weir,	CRNA,	MSN:	Investigadora	asociada	
Galloway	Endoscopy	Center	
7500	SW	87th	Ave	
Miami,	FL	33173	
Móvil:	(786)	999-9000	
Correo	electrónico:	weirm@vcu.edu	
	
Chuck	Biddle,	CRNA,	PhD:	Investigador	Principal		
Virginia	Commonwealth	University	
School	of	Allied	Health	Professions	
P.O	Box	980226	
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Richmond,	VA	23298-0226	
Teléfono:	(804)	828-9808	
Correo	electrónico:	nrsa@vcu.edu			La	investigadora	asociada	anteriormente	mencionada	es	la	mejor	persona	para	ponerse	en	contacto	con	respecto	a	preguntas	relacionadas	con	su	participación	en	este	estudio.		Si	tiene	alguna	pregunta	en	cuanto	a	sus	derechos,	no	dude	en	ponerse	en	contacto	con:		Oficina	de	la	Investigación		Virginia	Commonwealth	University	800	East	Leigh	Street,	Suite	3000	P.O.	Box	980568	Richmond,	VA	23298	Teléfono:	(804)	827-2157		Póngase	 en	 contacto	 con	 este	 número	 para	 preguntas	 generales,	 preocupaciones	 o	quejas	 relacionadas	 con	 la	 investigación.	 También	 puede	 llamar	 a	 este	 número	 si	 no	puede	comunicarse	 con	el	 equipo	de	 investigación	o	si	desea	hablar	 con	otra	persona.	También	 se	 puede	 encontrar	 información	 general	 en	 cuanto	 a	 la	 participación	 en	 los	estudios	de	investigación	en	http://www.research.vcu.edu/irb/volunteers.htm.			
CONSENTIMIENTO	
Se	 me	 ha	 dado	 la	 oportunidad	 de	 leer	 este	 formulario	 de	 consentimiento.	 Entiendo	 la	
información	 relacionada	 con	 este	 estudio.	 Las	 preguntas	 que	 quería	 hacer	 con	 respecto	 al	
estudio	 se	 han	 sido	 contestadas.	Mi	 firma	 significa	 que	 estoy	 dispuesto	 a	 participar	 en	 este	
estudio.	 Recibiré	 una	 copia	 del	 formulario	 de	 consentimiento	 una	 vez	 que	 haya	 aceptado	
participar.						Nombre	impreso	del	participante		 Firma	del	participante		 	 Fecha					Nombre	de	la	persona	que	realiza	la	discusión	de	consentimiento	informado.	(Impreso)		
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		 Firma	de	la	persona	que	realiza	el	consentimiento	informado.												Fecha		Discusión						Investigador	Principal	Firma	(Si	es	diferente	del	anterior)																		Fecha		
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Appendix D 
Research Subject Information and Consent Form (English) 
 
Title: Assessing Baseline and Post-Discharge Risk Factors in Subjects with and without Sleep 
Apnea Undergoing Endoscopy with Deep Sedation. 
 
VCU IRB PROTOCOL NUMBER: HM20008241 
 
Sponsor: AANA Foundation 
 
If any information contained in this consent form is not clear, please ask the study staff to 
explain any information that you do not fully understand. You may discuss this with your 
family or friends today, but we need your signed consent today to enroll. 
 
PURPOSE OF THE STUDY 
The purpose of this study seeks to compare changes in status of subjects with and without 
sleep apnea, before and after sedation. 
 
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT 
If you decide to be in this research study, you will be asked to sign this consent form after you 
have had all your questions answered and understand what will happen to you. 
 You will undergo a pre-surgery physical and questionnaire that all patients have before 
surgery. We will ask about your medical and surgical history, medicines, allergies, review your 
full medical record. This routine information will also be used in the study. In addition to this 
routine information, you will also be asked questions in order to complete the STOP-BANG 
questionnaire (helps determine likelihood of you having sleep apnea) and a 12-lead 
electrocardiogram (ECG) will also be done on the morning of the procedure. Both of these are 
in addition to your usual pre-operative preparation and are a necessary part of the research 
activities. 
 
If you consent to this study, we will ask you to wear a Heart monitor which is a type of 
ambulatory electrocardiogram (ECG). This device will record your heart’s electrical activity 
continuously while you move around doing your usual activities and during sleep. It will be 
attached with small pads or patches (electrodes) taped to your chest (see attached 
demonstration) after your procedure. You will also wear a Motion watch (like a Fitbit) and an 
oxygen monitor (measures the percentage of oxygen in your blood) before and after your 
procedure. The oxygen monitor will only be worn on your wrist and finger (see attached 
demonstration) whenever you rest or sleep. 
On the second day, you will return the heart monitor, motion watch. and oxygen monitor to 
the research team in the postage-paid envelope provided. You will be in a group of about 100 
other surgery patients and your information will remain confidential. You will wear the motion 
watch and pulse oximeter for 3 days and the Heart monitor for 1 day. Your total time 
commitment will be 4 days. 
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RISKS AND DISCOMFORTS 
There is a risk of minor discomfort when wearing the monitors, particularly the oxygen monitor. 
To ensure comfort, adjust the Velcro strap so that it is not too tight. 
You may wear it on either wrist. Also, wear the soft plastic finger probe on whichever finger you 
feel is more comfortable. The adhesive tape used to attach the electrodes of the heart monitor 
must be removed carefully to avoid skin irritation. We will ask questions to complete the STOP-
BANG questionnaire and do a 12 lead ECG Both of these research related activities will pose no 
additional risk to you and may provide additional important and useful information to clinicians 
who provide your care. 
There is also a potential risk for loss of confidentiality. This risk will be minimized by storing 
your information as securely and in keeping with all HIPAA and research confidentiality rules. 
 
USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION  
 
Authority to Request Protected Health Information 
The following people and/or groups may request my protected health information: 
• Principal Investigator and Research Staff     • Study Sponsor     
• Research Collaborators     • Institutional Review Boards    
• Data Safety Monitoring Boards    • Government/Health Agencies   
• Others as Required by Law  
 
Authority to Release Protected Health Information 
The Baptist Health System (BHS) may release the information identified in this 
authorization form from my medical records and provide this information to: 
• Health Care Providers at BHS • Principal Investigator and Research Staff      
• Health Care Providers at VCUHS   • Research Collaborators      
• Data Coordinators   • Institutional Review Boards      
• Data Safety Monitoring Boards      • Government/Health Agencies      
• Others as Required by Law • Study Sponsor 
 
Once your health information has been disclosed to anyone outside of this study, the 
information may no longer be protected under this authorization. 
 
 
Type of Information that may be Released 
The following types of information may be used for the conduct of this research: 
• Complete health record • Laboratory test results      
• History and physical exam   • X-ray reports      
• Consultation reports • Information about drug or alcohol abuse      
 
Expiration of This Authorization   
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• This authorization will expire when the research study is closed, or there is no need to 
review, analyze and consider the data generated by the research project, whichever is 
later. 
 
Right to Revoke Authorization and Re-disclosure 
You may change your mind and revoke (take back) the right to use your protected health 
information at any time. Even if you revoke this Authorization, the researchers may still use or 
disclose health information they have already collected about you for this study. If you revoke 
this Authorization you may no longer be allowed to participate in the research study. To revoke 
this Authorization, you must write to the Principal Investigator. 
 
BENEFITS TO YOU AND OTHERS 
You may not receive any direct benefit in this study. Your participation might help your health 
care team identify future patients at risk for cardiopulmonary events after surgery. 
 
COSTS 
There are no costs for your participation in this study except for your time to retrieve and wear 
the monitors before and after your procedure. 
 
PAYMENT FOR PARTICIPATION 
You will receive a $25 Visa gift card. In order to receive this gift card, you need to wear the 
monitors the day before and after the 24-hour period after your procedure. You must mail the 
monitors to the research team in the provided envelope. After the research team receives your 
monitors we will mail the gift card to your address you provide to us. 
 
ALTERNATIVES 
You have the option to not participate in this study. 
 
CONFIDENTIALITY 
Potentially identifiable information about you will consist of your medical history, physical, and 
monitor measurements. Data is being collected only for research purposes. 
Your data will be identified by a number code, not names, and stored in a password 
protected computer program. All personal identifying information will be kept in password-
protected files and these files will be deleted at the end of the study. Access to all data will 
be limited to study personnel. 
 
What we find from this study may be presented at meetings or published in papers, but your 
name will not ever be used in these presentations or papers. 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
 
You do not have to participate in this study. If you choose to participate, you may stop at any 
time without any penalty. You may also choose not to answer particular questions that are 
asked in the study. 
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Your participation in this study may be stopped at any time by the study staff or the 
sponsor without your consent. The reasons might include: 
• the study staff thinks it necessary for your health or safety; 
• you have not followed study instructions;  
• the sponsor has stopped the study;  
• or administrative reasons require your withdrawal. 
 
If you leave the study before the final regularly scheduled visit, return the 3 monitors in the 
provided envelope. You will not receive payment for participation if you do not fully complete 
monitoring for the full 24 hours after surgery. 
 
 
 
QUESTIONS 
If you have any questions, complaints, or concerns about your participation in this research, 
contact: 
Mercedes Weir, CRNA, MSN: Co-Investigator 
Galloway Endoscopy Center 
7500 SW 87th Ave 
Miami, FL 33173 
Cell: (786) 999-9000 
Email: weirm@vcu.edu 
 
Chuck Biddle, CRNA, PhD: Principal Investigator 
Virginia Commonwealth University 
School of Allied Health Professions 
P.O Box 980226 
Richmond, VA 23298-0226 
Phone: (804) 828-9808 
Email: nrsa@vcu.edu 
 
 
The co-investigator named above is the best person to call for questions about your 
participation in this study. 
 
If you have any general questions about your rights as a participant in this or any other 
research, you may contact: 
 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 3000 
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P.O. Box 980568 
Richmond, VA 23298 
Telephone: (804) 827-2157 
 
Contact this number for general questions, concerns or complaints about research. You may 
also call this number if you cannot reach the research team or if you wish to talk with 
someone else. General information about participation in research studies can also be found 
at http://www.research.vcu.edu/irb/volunteers.htm. 
 
CONSENT 
I have been given the chance to read this consent form. I understand the information about this 
study. Questions that I wanted to ask about the study have been answered. My signature says 
that I am willing to participate in this study. I will receive a copy of the consent form once I have 
agreed to participate. 
 
 
 
 
 
Participant name printed Participant signature   Date 
 
 
 
 
Name of Person Conducting Informed Consent Discussion (Printed) 
 
 
 
 
Signature of Person Conducting Informed Consent    Date 
Discussion 
 
 
 
Principal Investigator Signature (if different from above)   Date 
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Vita 
Mercedes Ermita Weir was born on September 7, 1967, in Buff Bay, Portland, Jamaica, 
West Indies. She is a naturalized citizen of the United States of America. She graduated from 
Kingsway High School in Kingston, Jamaica in 1983. She received her Diploma in Nursing from 
Kingston School of Nursing in Kingston, Jamaica in 1988 and her Bachelor’s in Nursing from 
Southern Adventist University, Chattanooga, Tennessee in 1994. After 10 years of Oncology and 
Critical Care Clinical experience she attended the State University of New York at Buffalo 
(SUNY Buffalo) and completed her Masters of Science in Nursing with a concentration in Nurse 
Anesthesia. In 2013 she was accepted as a doctoral candidate at Virginia Commonwealth 
University. She currently continues her clinical practice as Certified Registered Nurse 
Anesthetist (CRNA) in various Locums assignments across the United States. 
 
